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SUMMARY 
Adenosine, a strong coronary vasodilator, is a breakdown 
product of the myocardial high-energy phosphate ATP. ATP serves as 
the direct energy source for contraction of the heart. Chapter 1 of 
this thesis gives a general introduction on contractility dependent 
ATP-breakdown, the ATP-generating metabolism of the heart and the 
mechanism which leads to adenosine formation. The applications of 
purine biochemistry to cardiovascular research are summarized. 
In Chapter 2 the main evidence is given for the role of 
adenosine in the regulation of coronary vasodilation, in mediation 
of anticatecholaminergic effects as well as for the influence of 
adenosine on the electromechanical activity of the heart (2.1-2.3). 
The metabolism of adenosine, adenine nucleotides and other purines 
in the heart is summarized with emphasis on current clinical 
applications for diagnostic and therapeutic purposes. The potential 
use of purines for secondary prevention in clinical cardiology is 
discussed in relation to the experimental evidence from the 
literature. 
There is considerable evidence of a direct relationship between 
ischemic release of adenosine and other purines, with the 
subsequent post-ischemic ATP-content and the function of the heart. 
This can lead to new ways of therapy, e.g., intracoronary infusion 
of low doses of ATP or adenosine in the post-ischemic heart (2.4, 
2.5). 
The experimental section (Chapter 3 and Appendix Papers) gives 
details on purine metabolism in isolated perfused rat hearts under 
normoxic and ischemic conditions. 
Adenosine, infused into isolated hearts in micromolar 
concentrations is partly (15-20%) taken up by the heart, but mainly 
deaminated to inosine and broken down further to hypoxanthine, 
xanthine and urate. Urate is the major purine (70%) released from 
the normoxic rat heart. The maximal activity in rat heart 
homogenates of the enzyme responsible for the formation of urate 
(xanthine oxidase/dehydrogenase) correlates well with maximal rates 
of xanthine and urate formation in isolated ischemic hearts. Part 
of the enzyme is present in the oxidase form, and is capable of 
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generating free radicals, which can induce irreversible damage to 
the heart. 
The in vitro characteristics of other enzymes of purine 
metabolism (AMP-deaminase and S-adenosylhomocysteine hydrolase) are 
reported. Additional perfusion studies with specific inhibitors 
suggest a significant contribution by these enzymes to myocardial 
purine formation during normoxia (Appendix Papers II and IV) . 
Several lines of evidence suggest that the purines released from 
isolated rat hearts are in part degradation products of IMP or GMP 
instead of AMP. This appears to be especially so during normoxia. 
If hypoxanthine or inosine are added to the myocardial 
perfusate, they are slowly incorporated into the ATP-pool of the 
heart. The incorporation rate is increased after a previous 
ischemic period and can be further stimulated by simultaneous 
infusion of ribose. 
Evidence is presented that increased adenosine formation is 
directly related to increased formation of AMP (e.g., from ATP). 
The old hypothesis that adenosine is constantly produced at a high 
rate and nearly simultaneously reincorporated into AMP appears to 
be unrealistic. The results suggest an even tighter coupling of 
adenosine and purine release to the myocardial energy state than 
had already been assumed. A minor disbalance between ATP-breakdown 
and ATP-production will lead to increased adenosine and purine 
release and will eventually lead to significant loss of ATP and 
myocardial function. Some of the experiments point to ways of 
breaking through this vicious circle by defining conditions for 
enhanced myocardial ATP-repletion and possible restoration of 
function during reperfusion. 
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Chapter 1. PURINE METABOLISM AND THE HEART. GENERAL INTRODUCTION 
The energy that is needed for the continuous contraction of 
the heart is derived from the breakdown of ATP to ADP. Under 
aerobic conditions the major part of ATP is produced by 
oxygen-dependent catabolism of nutrients in the mitochondria (see 
figure 1). Mitochondrial ATP is transported via the adenine 
nucleotide translocator into the cytosol, where it can be used by 
the contractile proteins. 
FIG. 1 MAJOR PATHWAYS OF ATP FORMATION FOR MYOCARDIAL CONTRACTION 
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ATP is produced in the mitochondria by oxidative 
phosphorylation and transported to the cytosol via the so-called 
nucleotide translocator. Immediate transfer of the "high-energy" 
phosphate group of ATP to creatine phosphate (CrP) can occur via 
the mitochondrion bound enzyme: creatine phosphate kinase (CPK). 
Cytosolic CPK can produce ATP, which can be used for myocardial 
contraction. Fatty acids, glucose and lactate are substrates for 
the heart in the presence of sufficient amounts of oxygen. During 
hypoxia or ischemia lactate is released from the heart and 
ATP-production cannot take place sufficiently via anaerobic 
glycolysis. 
The heart supplies the other tissues with the prerequisites of 
normal cellular function by pumping oxygen-rich and 
nutrient-containing blood through the body. The heart muscle itself 
receives oxygen and nutrients via the coronary circulation. 
A delicate equilibrium exists between myocardial oxygen use (for 
contraction) , oxygen supply and coronary flow. This equilibrium can 
be regulated by reducing the amount of work performed by the heart 
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(ATP-breakdown) or by increasing the amount of coronary blood and 
oxygen that is supplied to the heart. Breakdown of ATP to ADP in 
the heart during contraction occurs at a very fast rate. About 4-8% 
of the total ATP (20-25 pmol/g dry wt) is broken down to ADP during 
a single contraction (59) . The ADP formed can be reconverted back 
to ATP through the action of creatine kinase with breakdown of 
creatine phosphate to creatine. In this way creatine phosphate 
provides a temporary buffer against rapid ATP-depletion (Figure 1) 
Elevated ADP levels can also be reconverted to ATP by the enzyme 
adenylate kinase with simultaneous formation of AMP. This AMP can 
be deaminated to IMP (a major pathway in skeletal muscle) , but it 
can also be dephosphorylated to adenosine, which is a potent 
coronary vasodilator (for details see Chapter 3.1). The 
phosphorylated, negatively charged purine nucleotides (ATP, ADP, 
AMP, IMP) will not readily pass through the cell membrane, but 
adenosine and other non- phosphorylated purines will. 
As soon as ATP-breakdown exceeds ATP-production, adenosine and 
other purines are released from the heart. Their appearance in the 
coronary circulation correlates with increased coronary flow and 
thereby increased oxygen supply to the heart. This can enhance 
ATP-formation and decrease adenosine release and coronary flow. The 
experimental evidence for the role of adenosine in coronary flow 
regulation is described in more detail in Chapter 2.2. Adenosine is 
broken down quickly to inosine and further to hypoxanthine, 
xanthine and urate, which will also appear in the coronary 
effluent. The more intricate details of purine metabolism are 
discussed in Chapter 3. 
These general features of myocardial adenine nucleotide and 
purine metabolism have been studied in more detail for the 
following reasons: 
1) Knowledge of the detailed mechanism of formation and breakdown 
of adenosine in the heart can provide insight into the 
regulation of coronary blood flow. In addition, several other 
physiological effects of adenosine on the heart have been 
documented. There is evidence of attenuation by adenosine of 
the deleterious effects of catecholamines in the ischemic 
heart as well as electrophysiological influences of adenosine 
4 
and ATP 1 both in clinical and in experimental studies (see 
Chapter 2) . 
2) The release of adenosine and its breakdown products (i.e., 
inosine 1 hypoxanthine 1 xanthine and urate) can be used to get 
an indication of the energy state of the heart. Similarly, 
determination of ATP and creatine phosphate concentrations in 
heart tissues, for example in peri-operative needle biopsies, 
can be used for the assessment of the "energetic quality" of 
heart tissue. Both in experimental and clinical studies, the 
increased release of purines is a good indicator of myocardial 
hypoxia or ischemia (Chapter 2.4). 
Pharmacologic agents that were found to protect the ischemic 
heart cause a decrease in ischemic purine release. Calcium 
antagonists can reduce net ATP-breakdown and purine release by 
either increasing ATP-formation through their coronary 
vasodilatory action or by decreasing ATP-breakdown through 
reduction of the afterload of the heart or through their 
negative inotropic effect (32, 34, 80). Beta-blockers can 
cause a decrease in purine release (80, 207), which has been 
increased by catecholamines. Determination of altered purine 
release is therefore a valuable tool in pharmacological 
studies of the heart. 
3) Several of the purines mentioned above (adenosine, inosine, 
hypoxanthine) can be incorporated into the myocardial 
ATP-pool, which will be severely depleted after prolonged 
ischemia. The ATP-level after hypoxia and reperfusion of the 
heart has been shown to correlate well with myocardial 
function (see Chapter 2.5). Stimulation of the resynthesis of 
the myocardial ATP-pool by giving purines to the heart could 
be a factor in promoting the velocity and quality of 
post-ischemic cardiac recovery. It could also provide 
additional protection against a lethal second ischemic attack. 
Moreover, myocardial protection or preservation during 
open-heart surgery or heart transplantation could also gain 
from well-defined purine administration, or prevention of 
purine release. 
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Chapter 2. PHYSIOLOGICAL IMPORTANCE OF MYOCARDIAL PURINE METABOLISM 
2.1. Historical introduction 
As early as 1929 Drury and Szent-GyOrgyi reported the coronary 
dilatory, and negative chronotropic and dromotropic actions of 
adenosine on the dog heart (42) . A year later adenosine effects on 
the human heart were reported (84). Effects of adenosine and 
related compounds on coronary flow of rabbit and dog hearts (213, 
214) were described in the early 1930 1 s. The vasodilatory action of 
purine and pyrimidine nucleotides was studied further (58) and an 
attempt was made to correlate muscle blood flow and adenine 
nucleotides in 1932 (160). In later years the coronary dilator 
properties of purine derivatives (55, 218) and of the 11 adenine-ATP" 
series (217) were investigated. The effect of ATP-infusion on the 
human electrocardiogram was reported in 1949 (212) and in 1955 ATP 
was found to be effective in the treatment of paroxysmal 
tachycardia (105, 193). 
Around 1960 the changes in myocardial adenine nuc1eotides and 
creatine phosphate during hypoxia were described in more detail 
(15, 130). Then in 1963 two articles appeared (by Berne and Gerlach 
and coworkers (16, 67)), which mentioned in their title the 
possible relationship between myocardial adenine nucleotide 
breakdown and coronary vasodilation. Berne's article (16) 
schematically introduced the hypothetical role of adenosine in the 
regulation of coronary flow. Since then numerous studies have been 
performed to elucidate the qualitative and quantitative aspects of 
the effects of adenosine on contractility, coronary flow, 
electrophysiology and biochemistry of the heart (for reviews 
see: 13, 17, 18, 150, 165, 178, 180, 195). In addition, adenosine 
has been found to influence various physiological processes in 
many other tissues. Examples of adenosine-related processes are: 
blood flow in skeletal muscle 1 liver, kidney, and brain, the rate 
of lipolysis in adipose tissue, neurotransmission in the brain, red 
cell production and platelet aggregation in blood and steroid 
production by adrenal cells (14, 106, 126, 150 1 172, 184 1 191). 
The following chapter summarizes the physiological effects of 
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adenosine on the heart as well as the role of adenosine, ATP and 
other purines in experimental and clinical cardiology. Emphasis is 
given to the relation between myocardial function and the 
ATP-content of the heart. 
2.2. Adenosine and coronary vasodilation 
Numerous experiments have been performed to further study the 
relationship between adenosine production and coronary 
vasodilation. Intracoronary infusion of adenosine (8, 25, 115, 169, 
176) or ATP, ADP or AMP causes dose-dependent vasodilation. The 
vasodilation caused by the adenine nucleotides results from their 
extremely rapid breakdown to adenosine {161, 192). However, this is 
no proof of coronary flow regulation by endogenous adenosine 
formation. Several physiologically relevant hemodynamic states in 
which coronary flow is increased have been experimentally induced 
and simultaneous changes in adenosine concentration have been 
determined, e.g., in perfusates of isolated perfused hearts, in 
coronary sinus whole blood or plasma, in myocardial biopsies, in 
freeze-clamped hearts, and in pericardia! fluid {5, 7, 28, 43, 77, 
80, 101, 113, 148). 
Hypoxia, reperfusion after ischemia {i.e., reactive hyperemia) 
and states of increased cardiac work are known to enhance coronary 
flow rates and adenosine release (7, 8, 40, 57, 80, 127, 133, 151 1 
194). Hypoxia can be induced by replacing oxygen in blood or 
perfusate by nitrogen or by infusion of inhibitors of mitochondrial 
function and oxygen use (cyanide, Amytal) (145, 159). 
Increase of myocardial work load can be achieved in vivo by 
increasing the afterload of the heart via aortic constriction or in 
isolated hearts by elevating perfusion pressure, and by increasing 
the heart rate through electrical stimulation {pacing) or by 
stellate ganglion stimulation (121, 131). Conscious ambulatory 
animals can be forced to increase total body and heart work in a 
treadmill or to just increase heart rate in response to a loud 
noise stress (5, 61). Infusion of catecholamines (epinephrine, 
norepinephrine), histamine or adrenergic drugs (isoproterenol, 
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dobutamide) elevate myocardial work and so does infusion of 
nicotine (50, 215) or calcium at higher than physiological 
concentrations {35) . Under all these conditions of stimulated heart 
work and consequently stimulated ATP-breakdown, good correlations 
were observed between coronary flow and adenosine production, 
either determined in heart tissue or in the coronary fluid (101, 
113, 127). In several instances similarly good correlations were 
observed between myocardial oxygen consumption and coronary blood 
flow (or coronary vascular resistance) and also between oxygen 
consumption and adenosine formation (44, lOlT 102T 131 1 168, 209). 
Still all these correlations might point only to a 
coincidental instead of a causal relationship between adenosine 
release and coronary vasodilation. No evidence, however, was found 
for the role of adenosine in the maintenance of an arteriolar 
vasodilation distal to a coronary stenosis (69)i a few authors 
failed to observe the relation between adenosine concentration and 
coronary flow (41). The technical problems of adenosine 
determination could have contributed to these negative results (44, 
77, 113). 
A second group of experiments which should be mentioned 
concerns the changing of the adenosine concentration or production 
in the heart and coronary arteries, either by infusion of 
adenosine, or by manipulations which alter the adenosine 
concentration, e.g., by stimulating or preventing the breakdown or 
by increasing its rate of formation, independent of increased work. 
A dose-dependent relationship between myocardial adenosine infusion 
and coronary flow was observed (170, 176). During postischemic 
reactive hyperemia, adenosine infusion can further increase the 
coronary flow (if submaximal) . Infusion of the enzyme adenosine 
deaminase, which breaks down adenosine, reduces the extent of the 
hyperemic flow (169). Modified low molecular weight adenosine 
deaminase has been used to potentiate its capacity to penetrate the 
interstitial space {166). The enzyme was found to decrease coronary 
flow during hypoxia, with simultaneous significant reduction of 
adenosine in the heart (166). Substances which can be broken down to 
adenosine in the extracellular space (ATP, ADP, AMP) also cause 
coronary vasodilation. 
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Administration of dipyridamole to the hypoxic isolated dog 
heart results in an increase of tissue adenosine levels without a 
simultaneous increase in adenosine release (107). This appears to 
contradict the hypothesis that increased adenosine release is 
responsible for coronary vasodilation. Later it has been 
demonstrated, however, that dipyridamole blocks uptake of released 
adenosine and transport to the vascular space (28) . Accumulation of 
adenosine in the interstitial fluid caused by dipyridamole has been 
demonstrated by measuring adenosine in pericardial infusates (102) • 
The relationship between coronary blood flow and adenosine release 
finally appears unchanged by dipyridamole (102) • Lidoflazine and 
mioflazine are chemically related drugs which, like dipyridamo~e, 
interact with myocardial adenosine sequestration (52, 91). 
Lidoflazine was described as an "adenosine-potentiator" and found 
to enhance coronary reactive hyperemia in conscious pigs (91). 
Administration of these drugs leads to large increases in 
myocardial adenosine concentration and increases postischemic 
function (52) . 
Not all coronary vasodilators act through an adenosine-related 
mechanism (e.g., papaverine) (170). For nitroglycerin it has been 
found that vasodilation was not paralleled by adenosine release; 
moreover, adenosine is more potent at small than at large coronary 
vessels, while the reverse is true for nitroglycerin (171). 
A special case is coronary vasodilation caused by acetate. 
Acetate is rapidly taken up by the heart (201) and converted to 
acetyl-CoA. This "activation" of acetate is an energy-requiring 
process during which ATP is converted to AMP. Increased AMP levels 
and coronary flow have been found in isolated hearts given acetate 
(216). AMP is a direct precursor of adenosine, which will be broken 
down quickly to inosine and further to (hypo)xanthine and urate. We 
found a dose-dependent linear increase in total purine formation by 
acetate {1-20 mM) infused into isolated rat hearts, with a 
simultaneous increase in coronary flow, without significant changes 
in cardiac function (Appendix Paper VI) . Arterial infusion of 
acetate in dogs results in increased release of purines from the 
coronary sinus with increased coronary flow (118). Again, however 1 
the full causal relationship between adenosine and vasodilation is 
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not complete. Therefore a clear picture of the underlying 
mechanism(s) of action is needed as well as a more quantitative 
description of the regulation of formation and breakdown of 
adenosine. As already mentioned, the determination of adenosine in 
blood and tissue has several technical pitfalls (44, 80, 113), 
which makes it extremely difficult to compute actual adenosine 
concentrations at the site of action from amounts (pmoles, umoles) 
found in tissue or blood (194). 
The first step in the determination of the mechanism of action 
of adenosine involved the finding of vasodilation resulting from 
infusion of large molecules (proteins) to which adenosine was 
chemically bound and which could not penetrate the cell (146, 147, 
177). Coronary vasodilation has been elicited by an AMP-protein 
conjugate (177), by adenosine linked to polysaccharide {146), and 
to polylysine (147). These conjugates are not taken up by the 
heart. All these experiments suggest that vasodilation by adenosine 
is a receptor-mediated process in which the extracellular adenosine 
concentration determines coronary smooth muscle relaxation. The 
properties of the vasodilatory adenosine receptor with regard to 
stereochemical specificity and character of the binding site have 
been investigated (114, 149). 
2.3. Other cardiac effects of adenosine and possible mechanisms of 
action 
Besides the coronary vasodilatory action of adenosine, Drury 
and Szent-GyOrgyi (42) also described other effects of adenosine on 
the heart. Their observations included inhibition by adenosine of 
electrical conduction and impulse generation in the 
atrioventricular and sinus node and depression of contractile 
force, especially in the atrial muscle. 
The negative inotropic effect of adenosine is rather weak in the 
ventricle and in isolated perfused hearts (47, 129), but can be 
clearly demonstrated as antagonistic to catecholamine-enhanced 
contractile activity (9, 175). These anti-catecholaminergic effects 
of adenosine can be important during ischemia when ischemia-induced 
catecholamine release will enhance ATP-breakdown and speed up the 
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decrease of cardiac function. A decrease of heart rate by adenosine 
(75) can slow down ATP-utilization and delay the onset of 
irreversible damage. 
The inhibition of atrial slow action potentials in 
adenosine was explained by inhibition of 
guinea pig 
ca2+-influx (49, hearts by 
173). The involvement of an extracellular adenosine receptor (or 
11 purinergic 11 receptor (22, 23)) has been mentioned in the previous 
paragraph. 
The link of the adenosine receptor to adenylate cyclase and 
thereby to increased cyclic AMP formation has been suggested (for 
short review: see Schlitz 1985 (183)), but is not altogether clear. 
Inhibition of breakdown of cAMP by intracellular adenosine has also 
been suggested. This would lead to increased potassium conductance 
and decreased slow inward current of calcium. The interested reader 
is referred to a number of articles to form his own opinion on the 
exact mechanism of the electromechanical action of adenosine on 
atrial, ventricular, vascular and neural tissue of the heart (9, 
11-13, 20, 23, 37, 39, 46, 47, 75, 119, 120, 129, 182, 205). 
2.4. Adenosine, ATP and other purines in clinical cardiology 
The rapidly increasing knowledge of myocardial purine 
metabolism has already led to diagnostic and therapeutic 
applications in clinical cardiology and cardiac surgery. This could 
lead to other clinical applications in the future. Diagnostic 
applications will be discussed separately from therapeutical and 
secondary preventive aspects. 
Diagnostics 
The myocardial (intracellular) content of ATP and creatine 
phosphate is a good indicator of ischemia or previous ischemia (6, 
26, 27, 38, 74, 94, 97, 134). The efficacy of cardioprotective 
measures during human aorta-coronary bypass surgery has been 
assessed by the determination of ATP and creatine phosphate in 
heart biopsies (53, 97, 204). In similar studies the additional 
protective effect of calcium antagonists in cardioplegic solutions 
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was reflected by better myocardial ATP preservation (54) . The 
protective effect of lidoflazine, administered to patients 
subjected to aorta-coronary bypass surgery, was reflected in better 
postoperative high-energy phosphate contents and better myocardial 
function (52), In addition, ATP-determinations could be valuable 
predictors of the quality of donor hearts used for transplantation. 
It is tempting to redefine myocardial ischemia as a metabolic state 
where the ratio of ATP-breakdown over ATP-formation is increased. 
Even during hypothermic cardiac arrest ATP-decline has been 
reported (38, 97). Minor decreases in myocardial ATP-content are 
difficult to detect, however, which can explain the repeated 
failure to detect significant changes in ATP-levels after short 
periods of ischemia, 
An alternative to determinations of ATP in cardiac biopsies or 
excised papillary muscle is determination of the released 
catabolites of ATP into the coronary effluent or their accumulation 
in the heart. Release of adenosine from the human heart was first 
described by the group of Fox (48, 60, 61). Other authors have also 
reported purine release from the human heart under ischemic 
conditions (96 1 109-112). In our laboratory we repeatedly {79, 158, 
185) demonstrated increased release of hypoxanthine from human 
hearts during atrial pacing stress tests (APST) and after 
percutaneous transluminal coronary angioplasty (PTCA). Kaijser and 
collaborators (43) determined release of adenosine, inosine and 
hypoxanthine in patients with ischemic heart disease. As already 
described, adenosine is rapidly broken down in the heart to inosine 
and hypoxanthine and, in most species, to xanthine and urate. 
Determination of hypoxanthine is presumably the most sensitive 
indicator of human myocardial ischemia, because it is a major 
purine released from the human heart (43). Urate release is 
difficult to detect because of the high normal blood urate content. 
An alternative biochemical marker of ischemia is lactate release. 
It has been found in dogs that increased hypoxanthine release can 
occur in situations, where lactate is still being extracted (206), 
Similarly, in patients after an atrial pacing stress test, 
hypoxanthine release was still observed when lactate was again 
extracted by the heart after a temporary release phase (79). 
A correlation between blood levels of purines and severity of 
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myocardial disease has been observed (21, 48, 62, 70, 76), but 
other factors than ischemic myocardial purine release could be 
relevant to this observation (125, 137, 219). 
Therapeutics and prevention 
It has been suggested (210) that adenosine is a mediator of 
the paroxysmal bradycardias and tachycardias, which characterize 
the 11 sick-sinus syndrome 11 • The adenosine antagonist theophylline 
(210) was suggested as a therapeutic agent. 
On the other hand ATP, adenosine, and the adenosine re-uptake 
inhibitor dipyridamole are applied with good results for the 
prevention and therapy of paroxysmal supraventricular tachycardia 
(13, 37, 71, 105, 154, 193). Apart from the known 
electrophysiological effects of adenosine and ATP, elevation of the 
intracellular ATP-pool could be an additional mechanism of action. 
If ATP is applied intracoronarily or intravenously, it is rapidly 
broken down to adenosine (161, 192) and in most species the 
physiological actions of adenosine are similar to those of ATP (12, 
13), although different "purinergic" receptors have been suggested 
for these substances {22, 23). 
Beneficial effects of the adenosine catabolite inosine on the 
ischemic heart have been reported (36, 95, 189). The exact mode of 
action is unknown, but coronary vasodilation by inosine has been 
reported (95) as well as increased insulin levels in blood after 
inosine administration {189) . Elevated insulin will enhance glucose 
utilization and thereby ATP formation. Enhanced net ATP-formation 
via the incorporation of hypoxanthine derived from inosine can be 
another important mode of action (Appendix Paper III) , 
The xanthine oxidase/dehydrogenase inhibitor allopurinol 
prevents the degradation of hypoxanthine to xanthine and urate. Its 
described beneficial action on the heart (2, 24, 116) might 
therefore derive its effect from the increase of hypoxanthine 
incorporation into myocardial ATP. A mechanism related to the 
prevention of free radical-induced cellular damage might also be 
operative, however, in the case of allopurinol (24, 82, 198). 
13 
As already mentioned, lidoflazine, a drug which prevents the 
release and washout of the ATP-catabolite adenosine from the heart, 
was found to protect the heart during a peri-operative period (52) • 
The mechanism of action can be considered as preventive, when it 
acts via acceleration of adenosine incorporation into the 
myocardial ATP-pool. Additional effects of adenosine elevation in 
the heart by this drug might on the other hand constitute a 
therapeutic effect (see Chapter 2.3). The beneficial influence of 
high doses of adenosine, with or without an inhibitor of adenosine 
breakdown has been reported in several experimental studies (45, 
56, 85, 88, 98, 123, 156, 188). 
It should be mentioned that adenosine itself (or ATP) cannot 
be administered intravenously in high doses. Severe hypotension 
(90) and possibly renal vasoconstriction will result. Moreover, a 
role for adenosine in the occurrence of immunosuppression is 
suggested from the existence of the inherited immunodeficiency 
syndrome "adenosine deaminase deficiency 11 (187) . 
The possible importance of enhanced ATP-repletion by giving 
purines (adenosine, inosine, hypoxanthine) and substances which 
might enhance the ATP-forming processes (e.g., ribose) is currently 
under investigation by numerous groups of researchers, but mostly 
still in animal models. In order to clarify the importance of 
ATP-repletion in the post-ischemic heart, we will discuss the 
relationship between myocardial function and myocardial ATP-content 
in the next chapter. 
2.5. Adenine nucleotides, purine metabolism and myocardial function 
The direct relationship between myocardial function, oxygen 
consumption, coronary flow and adenosine production has been 
described in a previous paragraph. Because adenosine is an 
ATP-catabolite, a similar, but more intricate relationship between 
myocardial ATP-rnetabolism, function, coronary flow and oxygen 
consumption appears logical. 
Norrnoxic myocardial ATP-contents fall in the range between 
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20-25 pmol/g dry wt, The rates of ATP-breakdown and formation have 
been estimated between 150 and 600 pmol/g dry wt per minute (81, 
103). The extremely high turnover-rate of cardiac ATP, together 
with compartmentalization of its formation and breakdown make it 
extremely difficult to adequately describe the relationship between 
ATP and function in detail. Myocardial purine release, e.g. 1 during 
prolonged ischemia 1 hypoxia, increased workload or catecholamine 
stress 1 can alter the myocardial adenine nucleotide content 
considerably (80, 94). In normoxic control hearts or hearts that 
are reperfused after reversible ischemia or hypoxia, ATP makes up 
75 to 80% of the adenine nucleotides (ATP + ADP + AMP). Total 
adenine nucleotide loss is therefore under these conditions mainly 
reflected in loss of ATP. The importance of calcium, potassium, 
sodium, pH and catecholamines as determinants of cardiac 
contractile function in the non-irreversibly damaged, reperfused 
heart is beyond question, but there is also considerable evidence 
that contractile function is directly related to the ATP content of 
the heart. A short summary of the evidence for a direct 
relationship between post-reperfusion function of the heart and ATP 
content will be given. 
Coronary artery occlusion of dog hearts in vivo resulted in a 
more than 50% reduction in the ATP-content of non-infarcted heart 
muscle and an even greater reduction in infarcted tissue {72-74). 
Even after ten days the ATP content was still less than 80% of 
controls in non-infarcted tissue (73). Decreased myocardial 
function (expressed as stroke work or dP/dt) paralleled ATP-content 
in these studies. Decreased myocardial ATP contents after short and 
reversible ischemia in vivo are restored very slowly (27, 87, 94, 
122, 157, 199, 200). A similar slow restoration is found for the 
decreased post-ischemic function (27 1 94, 100). In a variety of 
other studies a good correlation was observed between ATP-content 
and post-hypoxic or post-ischemic myocardial function, irrespective 
of the way in which function was determined. Ventricular septal 
preparations of both newborn and adult rabbit hearts after ischemia 
(144) or hypoxia (92, 93) followed by reperfusion showed the same 
correlation, with newborn hearts less susceptible to loss of ATP 
and loss of function. Isolated, perfused rabbit hearts subjected to 
different temperatures (hypothermia) during ischemia and protected 
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with the calcium antagonist nifedipine (138) restored their 
function in good correlation with the residual ATP-content. Similar 
results were found with the calcium antagonist verapamil in 
isolated rat hearts (211). It has been repeatedly shown in our 
laboratory that several calcium antagonists (i.e., diltiazem, 
nifedipine, nisoldipine, bepridil) protect the ischemic heart by 
decreasing ATP-catabolite release (32, 34, 35), which results in 
better preservation of ATP (80) . In earlier studies in our 
laboratory (196) 1 we have obtained a relation between ATP-content 
and function in rat hearts subjected to different degrees of 
hypoxia (Fig. 2). The curve shown is rather similar to other curves 
obtained after ischemia or hypoxia followed by reperfusion (92, 93, 
155) • 
FIG. 2 RELATION BETWEEN MYOCARDIAL ATP-CONTENT AND CONTRACTILITY 
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ATP-contents were determined in isolated rat hearts, 
subjected to varying degrees of hypoxia (8) or ischemia (O) . 
Myo~ardial function is given as percentage of prehypoxic or 
pre-ischemic function. Apex displacement is used as a measure 
of function. Data are redrawn from Starn & De Jong, 1977 (ref 196). 
Several authors, however (86, 139, 202), have suggested that 
there is no linear relationship between myocardial function and 
ATP-content after severe ischemia and reperfusion. One group (139) 
presents evidence that ischemic lactate accumulation is an 
additional important factor which can cause depression of 
post-ischemic contractile function. Another group (86) negates the 
ATP-function correlation but simultaneously presents evidence of a 
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good correlation between ATP-content and recovery of coronary flow 
in an isolated working heart preparation subjected to ischemia and 
reperfusion. All find, however, that high ATP levels correlate with 
good functional recovery and low ATP levels with poor or no 
functional recovery. 
One important implication of the ATP - function relationship 
is that a heart subjected to a second period of ischemia is bound 
to completely loose its function, and very fast, if ATP-levels have 
not been restored in the inter-ischemic period. 
A second implication has to do with the observation that ischemic 
ATP-decline, as for instance during open-heart surgery, is bound to 
proceed beyond a point of no return. Hypothermia and cardioplegic 
arrest prevent ischemic ATP-breakdown to a large extent. Still 
significant ATP-decline can proceed during prolonged hypothermic 
arrest (83), post-operative function of the heart declines, while 
sensitivity to a period of accelerated ATP-breakdown will be 
increased (26, 94, 97). 
Considerable experimental effort has therefore been centered on 
ways to speed up the restoration of the myocardial ATP-content 
during reperfusion. Incorporation of hypoxanthine (inosine) and 
adenosine (ATP) are studied most in this respect (4, 36, 45, 56, 
83, 85, 881 89, 95, 98, 123, 124, 156, 188, 189, 208, 220). 
A discouraging observation, however, was recently reported by the 
group of Schaper (83) , who observed in intact dog preparations made 
ischemic by coronary occlusion, that accelerated increase of the 
post-ischemic myocardial ATP-pool by adenosine infusion did not 
result in better functional recovery. High adenosine 
concentrations, as found in these hearts could have depressed 
myocardial function. Another negative aspect of adenosine 
administration could be the fact that this will increase the flux 
through the xanthine oxidase pathways, with a chance of increased 
free radical formation (see also Chapter 3.2). 
A factor which could influence the rate of ATP-restoration is 
phosphate depletion during ischemia, because the net reaction for 
adenosine incorporation is: Adenosine+ 3 Pi (i.e., inorganic 
phosphate) to give ATP. The role of phosphate in myocardial 
processes has not been systematically studied, although perfusion 
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without phosphate in the medium {197) results in decreased coronary 
flow, decreased oxygen consumption and lower levels of ATP and 
creatine phosphate in the heart. Hypophosphatemia in vivo results 
in myocardial adenine nucleotide breakdown and loss of function 
(19, 65). Very recently, evidence was presented that inorganic 
phosphate could indeed be rate-limiting for ATP-repletion by, for 
instance, adenosine (51). Earlier studies have suggested a role for 
inorganic phosphate accumulation in the early 11 pump failure" of the 
ischemic heart (108). 
The adenine nucleotide levels normally found in in vivo or 
well- perfused hearts are quite similar in human, pig, dog, rat, 
rabbit and guinea pig. Moreover, these values appear to be about 
the maximally obtainable levels (89, 156). The incorporation rate 
of radioactively labeled adenosine into rat cardiac adenine 
nucleotides was similar in normoxic hearts and in hearts to 
previously submitted ischemia (which resulted in a 50% decline in 
adenine nucleotides) and reperfusion (156). Still, when perfusion 
with adenosine continued for 5 hours, all hearts were found to 
contain the same amounts of ATP, ADP and AMP, which were moreover 
similar to the levels in controls before the 5-hour perfusion 
period (156). 
As an alternative for adenosine infusion, ATP has been used. 
ATP is broken down quickly to adenosine in the heart (161, 192) and 
can therefore give high local concentrations of adenosine and 
phosphate. Beneficial effects of ATP-MgCl 2 on the heart during 
reperfusion after global ischemia have indeed been reported (99, 
124). In both studies low doses (<0.1 mM) gave better results than 
high doses ()1 rnM). From these studies it was concluded that 
"post-treatment with low-dose ATP-MgCl 2 may be beneficial in cases 
following myocardial infarction as an adjunct to thrombolysis or 
angioplasty 11 • 
Some of our experiments (Appendix Papers III & VI) have been 
concerned with the regeneration of the myocardial ATP-pool. We have 
found that inosine and hypoxanthine {20 pM) are incorporated into 
myocardial ATP (and GTP) at a relatively slow rate. After ischemia, 
the velocity of this process is about doubled and ribose further 
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stimulates the process (Appendix Paper III). The maximal velocity 
of hypoxanthine incorporation that we found would restore a 20% 
depleted ATP-pool in 48 hours. Low concentrations of adenosine are 
incorporated at a faster rate. At 2 pM adenosine 20% of the adenine 
nucleotide pool might be restored in 4 hours (Appendix Paper V) . 
Both the fundamental aspects and clinical possibilities of ATP 
restoration in the heart deserve much further attention, with 
adenosine- mediated processes as still the most promising. 
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Chapter 3. FORMATION AND BREAKDOWN OF ADENOSINE IN THE HEART 
3.1. Details of myocardial purine metabolism 
Physiologically relevant adenosine formation in the heart is 
associated with a disbalance between the very rapid formation and 
breakdown of ATP (see Chapter 2.2). 
It is therefore necessary to study adenosine formation in a 
preparation (e.g., the isolated, beating heart) which has a 
considerable rate of ATP-turnover and in which a disbalance of 
ATP-formation and breakdown can be experimentally induced (e.g., by 
hypoxia or ischemia). Additional studies on hornogenates or purified 
enzymes from the heart can give insight into the detailed 
regulation and maximal velocity of certain steps in the metabolic 
pathways involved. 
Possible complications can arise from the fact that the heart 
consists of several cell types, such as myocytes, fibroblasts, 
vascular cells, which might have a distinctly different adenosine 
metabolism. Moreover, it could well be that intracellular 
compartmentalization of enzymes and substrates (e.g. 1 in 
mitochondria or cytosol) impedes extrapolation of studies on 
homogenates to the metabolism of the whole heart. 
In this chapter we will describe the major pathways of the 
myocardial metabolism of purine nucleosides and oxypurines. It will 
be shown that it is not possible to directly quantify adenosine 
formation and breakdown 1 but that several other metabolic pathways 
influence the quantification of adenosine metabolism 1 when 
determined in the perfused heart. Figure 3 summarizes myocardial 
purine metabolism. 
Adenosine formation occurs via dephosphorylation of AMP by the 
enzyme 5'-nucleotidase or by breakdown of S-adenosylhomocysteine by 
S-adenosylhomocysteine hydrolase. S-adenosylhomocysteine is a 
product of the cellular methylation cycle (see: Appendix Paper IV) • 
Adenosine can be released from the heart 1 broken down to inosine by 
adenosine deaminase, or reincorporated into the adenine nucleotide 
pool by ATP-dependent phosphorylation to AMP through adenosine 
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kinase (Fig. 3). 
Inosine can be broken down to hypoxanthine by nucleoside 
phosphorylase. Hypoxanthine can be salvaged by incorporation into 
IMP (hypoxanthine phosphoribosyltransferase) , or broken down to 
xanthine and urate, both by the enzyme xanthine 
oxidase/dehydrogenase. Breakdown of IMP or GMP can result in 
additional release of xanthine and urate. For more elaborate 
reviews on myocardial and general purine metabolism, see references 
(62, 80, 94, 122, 132, 152, 178, 180). 
FIG. 3 MAJOR PATHWAYS AND ENZYMES OF MYOCARDIAL PURINE METABOLISM 
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IMP can be formed from small precursor molecules by de novo 
synthesis. Both hypoxanthine salvage and de novo synthesis 
proceed to AMP via the adenylosuccinate pathway (9) . 
Dotted lines: breakdown of IMP and GMP to xanthine. 
The complexity of purine metabolism imposes a number of 
problems on the study of adenosine formation from determinations of 
purines in perfusates. Several questions have to be answered, 
which, moreover, are strongly interrelated. These questions concern 
the following major topics: 
a) How much adenosine catabolites and total purines are released? 
b) Are all purines that are released derived from breakdown of 
adenosine? 
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c) Is purine release a good measure of total purine and adenosine 
formation or is the reincorporation of hypoxanthine and 
adenosine important? 
d) The source of adenosine: AMP or S-adenosylhomocysteine? 
e) How is increased adenosine formation regulated? 
These questions cannot be dealt with simultaneously or in a single 
experimental approach. In the following paragraphs we will relate 
our experimental findings to the above described major questions. 
3.2. Quantification of all major purines released from the heart 
The importance of xanthine oxidase/dehydrogenase. 
In the past many authors solely determined adenosine, inosine 
and hypoxanthine in coronary perfusates (7, 8, 174). This is only 
an adequate measure of purine formation, if no significant amounts 
of xanthine and urate are formed. 
Several lines of investigation have led to a quantification of the 
importance of urate and xanthine formation in the isolated perfused 
rat heart under various conditions: 
1) Xanthine oxidase/dehydrogenase (XO/XD) activity has been 
determined in rat heart homogenates. A maximal activity of 
around 30 nmo1/min per g wet weight is found (Appendix 
Paper I) . 
2) During normoxia and anoxia hypoxanthine release is 
significantly increased by infusion of the xanthine oxidase 
inhibitor allopurinol (Appendix Paper I). 
3} Infusion of s- 14c hypoxanthine and s- 14c inosine results in 
formation of labeled xanthine and urate (Appendix Paper III) . 
From these experiments apparent XO/XD activities of 
16-27 nmol/min per g wet wt. can be calculated. Infusion of 
inosine appears to enhance the apparent XO/XD activity as 
compared to that found during hypoxanthine infusion and so 
does the simultaneous infusion of ribose with hypoxanthine 
(Appendix Paper III) . 
4) Infusion of adenosine also results in formation of xanthine 
and urate. This has been demonstrated before by others (161). 
The apparent XO/XD activities that we compute are around 
12 nmol/min during 1 ?M adenosine infusion and already reach 
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20 nmol/min per g wet wt at infusion of 5 ?M adenosine (Appendix 
Paper V). 
On combining the results we conclude that catabolism of infused 
adenosine in the rat heart proceeds up to urate at a fast rate, 
even if low concentrations of adenosine are infused. 
The relative importance of purine catabolism up to urate is also 
apparent from our finding that total purine release from 
well-oxygenated hearts consists for more than 70% of urate 
(Figure 4). During ischemia and hypoxia, however, this percentage 
drops, and adenosine, inosine and hypoxanthine become the main 
purines that are released (Appendix Paper VI) . 
FIG. 4 CONTRIBUTION OF ADENOSINE, INOSINE AND URATE TO TOTAL 
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Urate (--.) is the major purine released during 
normoxia, when total purine release is low. The contribution 
of inosine (~) increases during hypoxia and low-flow 
ischemia, when total release is higher. Adenosine (Q---0) 
increases more slowly than inosine. The contributions of 
hypoxanthine and xanthine are not shown. These are about 
equal and never amount to more than 15% each. 
Recently, we observed that hearts of newborn rats (10 days 
old) release about tenfold less urate than adults, presumably 
because XO/XD activity is significantly lower in these young 
hearts. Neonatal rat hearts (1-2 days old) have thirtyfold lower 
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XO/XD activities than adult hearts {B. Schoutsen, personal 
communication). It appears, moreover, that xanthine oxidoreductase 
activity is only present in vascular endothelial cells (68). 
The recent finding (10) that urate is also the major purine (80% of 
total) released from the normoxic guinea-pig heart corroborates our 
results in rat hearts and throws a different light on quantitative 
studies on adenosine formation in this species (8). 
Xanthine oxidase/dehydrogenase activity in the heart is mainly 
present in the dehydrogenase form, which produces NADH from NAD+ in 
the course of urate formation. A part of the enzyme (20%) is 
present in the oxidase form (Appendix Paper I). Xanthine oxidase 
produces superoxide anion radicals from oxygen. During ischemia 
part of the dehydrogenase form can be converted into the oxidase 
form (24). Ischemia and reperfusion provide both substrate 
(hypoxanthine) and oxygen for the oxidase and increased free 
radical generation occurs, which causes at least part of the 
normally observed reperfusion damage (82, 186). The extent of 
reperfusion damage can be reduced by the xanthine oxidase inhibitor 
allopurinol. Because the enzyme is strictly located in the 
endothelium, it appears that reperfusion damage could have the 
endothelium as a major target (68) . 
3.3. Are all released purines adenosine catabolites? 
If all purines that are released from the heart are adenosine 
catabolites, quantification of adenosine formation and release 
would be much simplified. 
Purine formation from breakdown of GMP and IMP instead of AMP 
cannot be excluded as IMP accumulation has been repeatedly 
described in ischemic or anoxic perfused hearts and in isolated anoxic 
cardiomyocytes (66, 67, 85, 86, 153). Moreover, in skeletal muscle IMP 
accumulation is the predominant pathway of ATP catabolism {30, 62) 
during hypoxia. If IMP is broken down to inosine at a similar rate as 
its rate of formation, no accumulation will be found in the heart. 
Our experiments (Appendix Paper II) on purified AMP-deaminase, the 
enzyme which catalyzes the formation of IMP from AMP, demonstrate a 
regulation by the adenylate energy charge (3), which is expressed as: 
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(ATP + ~ADP)/(ATP + ADP +AMP). These results would suggest a very 
low normoxic rate of IMP-formation in relation to the maximal 
activity of the enzyme. The maximal activity, however, is several 
orders of magnitude higher than normoxic purine release. Several 
other factors (creatine phosphate, inorganic phosphate) (see 
Appendix Paper III) have been reported to influence AMP-deaminase 
activity in vitro. 
When an inhibitor of adenosine deaminase is infused during 
ischemia, a large increase in adenosine release is observed 
(Appendix Paper VI) without alteration of total purine release. 
Still, adenosine only amounts to 60% of ischemic purine release 
during infusion of EHNA (Erythro-9-)2-hydroxy-3-nonyl adenine). 
EHNA is a very effective inhibitor of dearnination of infused 
adenosine. During normoxia EHNA infusion gives only a minor 
increase in adenosine release. This points to an important 
contribution of IMP- or GMP-breakdown to normoxic purine release. 
It has been shown that the enzyme, which is most probably 
responsibe for the breakdown of AMP and IMP (i.e., cytosolic 
5'-nucleotidase) dephosphorylates IMP and AMP equally fast (63, 64, 
135, 181). The enzyme reaches its half-maximal activity at very low 
concentrations (5-20 pMl of IMP and AMP (63, 64, 135, 181). Most of 
the AMP found in acid extracts of heart is presumably bound (to 
proteins). The actual AMP concentration is calculated (104, 190) at 
2-5 micromolar. IMP is present in hearts at 0.1 prnol/g dry wt. or 
more (86, 203). IMP could therefore be present at several-fold 
higher free concentrations than AMP and be hydrolyzed at a faster 
rate during normoxia. Other authors have made similar suggestions 
for normoxic and ischemic guinea pig hearts (180, 203). 
In conclusion: Especially during normoxia, purine release by rat 
heart is only partly derived from adenosine catabolism. 
3.4. Salvage of hypoxanthine and reincorporation of adenosine 
The potential importance of restoration of the myocardial 
ATP-pool and function of the heart via salvage of hypoxanthine or 
reincorporation of adenosine is described in Chapter 2.5. 
Infusion of radioactively labeled hypoxanthine and inosine 
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(Appendix Paper III) results in incorporation of radioactivity in 
the myocardial adenine nucleotide and guanine nucleotide pool. The 
incorporation is faster in hearts that have been subjected to a 
previous period of ischemia as compared to normoxic controls. 
Simultaneous infusion of ribose stimulates the incorporation 
further. These incorporation rates are about one order of magnitude 
lower than the normoxic purine release. Reincorporation of 
endogenously formed hypoxanthine will therefore not substantially 
influence the estimation of purine formation and release from the 
heart. 
FIG. 5 ADENOSINE UPTAKE AND INCORPORATION INTO ADENINE NUCLEOTIDES 
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Incorporation rates of 14c-adenosine into ATP as 
reported by Namm (D; ref. 136), Aussedat (0; ref. 4) and Newby 
(V; ref. 140) and apparent uptake rates as determined by us 
(G; App. paper V) are linear with the adenosine concentration 
infused up to 20 - 30 pM. (All experiments in rat hearts) . 
In the clinical situation, however, a four- to five-fold 
stimulated recovery rate of myocardial ATP-content could be of 
enormous significance. In models of cardiac ischemia in the rat (in 
vivo) the stimulatory effects of inosine and ribose infusion on 
ATP-regeneration have been repeatedly demonstrated (36, 208, 220). 
Inosine (Trophicardyl) is used as a cardiotonic drug in some 
European countries. Good research as to its effects in patients has 
not been carried out, however. 
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Adenosine infusion into isolated rat hearts (Appendix Paper V) 
gives a concentration-dependent uptake of the nucleoside. These 
uptake rates are similar to the rates of incorporation of 
radioactive adenosine into adenine nucleotides that were determined 
by other authors (4, 136, 140, see Figure 5). Several factors 
determine the incorporation rate of infused adenosine. Apart from 
possible limitations by transporti infusion of too high 
concentrations can inhibit adenosine kinase and can have negative 
hemodynamic and electromechanical effects on the heart. Low 
concentrations are therefore necessary, but then the actual rate of 
input at a given coronary flow might be lower than the possible 
rate of incorporation. The fast deamination (Appendix Paper V) 
probably gives the most severe restriction of adenosine 
availability, however. 
The use of ATP or AMP as adenosine precursor can possibly lead to 
high aCenosine concentrations near the cellular membrane with a 
resultant increased uptake (64) as compared to similar 
concentrations of infused adenosine. 
3.5. Two sources of adenosine: S-adenosylhomocysteine and AMP 
The constant formation of small amounts of adenosine from 
S-adenosylhomocysteine in the normoxic rat heart, as suggested from 
studies which determined the rate of the cellular methylation cycle 
is confirmed by our experiments with homocysteine infusion 
(Appendix Paper IV). Although this rate of adenosine formation is 
only a small portion of total purine release, there are several 
arguments which enhance its importance. From our perfusion studies 
with an adenosine deaminase inhibitor (EHNA) it is concluded that a 
significant part of normoxic purine release is not derived from 
breakdown of AMP to adenosine (Appendix Paper V) • This increases 
the relative importance of adenosine production from 
S-adenosylhomocysteine during normoxia. During ischemia, however, 
adenosine formation from its homocysteine adduct can be neglected. 
The role of the enzyme in the guinea pig heart appears to be even 
greater, because the maximal activity of the enzyme is several-fold 
higher in that species (179). Elevated serum levels of 
homocysteinei which will block adenosine formation from 
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s-adenosylhomocysteine occur in certain inborn errors of metabolism 
(78, 128). An increased incidence of arteriosclerosis has been 
found in this disease (78, 128). It is interesting to speculate 
about decreased myocardial adenosine release, possible increased 
vascular cell stiffness and induction of arteriosclerosis in this 
disease state (68). Especially since homocysteine-thiolactone 
infusion is found to reduce myocardial reactive hyperemia, although 
this last observation has been challenged (167). 
Our later experiments with infusion of an adenosine kinase 
inhibitor suggest (Appendix Paper VI) that adenosine formation from 
AMP is several-fold higher than adenosine formation in the 
methylation cycle. A large part of adenosine is immediately 
reincorporated into AMP. One can argue, however, that the isolated 
glucose-perfused rat heart will have a worse balance between 
ATP-formation and ATP-breakdown than the heart in vivo and 
therefore produce more adenosine from AMP than the latter. The 
importance of increased AMP-formation for increased adenosine 
production will be further discussed in paragraph 3.6. 
3.6. Adenosine cycling and the regulation of increased adenosine 
formation 
One of the first hypotheses about the regulation of adenosine 
formation suggested that adenosine was formed at a relatively high 
rate from AMP and immediately reincorporated again into AMP by 
adenosine kinase (1, 143). This enzyme has a half-maximal activity 
at very low concentrations of adenosine (Km: 0.5-1 micromolar) (29, 
31) . The kinase is inhibited by adenosine concentrations higher 
than 10 to 20 pM (29, 31, 143). Increased adenosine formation from 
AMP was assumed to result in increased adenosine release by 
decreased reincorporation. Because of the rather high maximal 
activity of adenosine kinase (40-200 nmol/min per g wet wt.) and 
the fact that adenosine phosphorylation requires ATP, this 
regulatory mechanism would be energy consuming. 
Infusion of a potent inhibitor of adenosine kinase in isolated 
normoxic rat hearts (140) has been found to result in unchanged 
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release of adenosine, inosine and hypoxanthine. However 1 during 
normoxia 1 urate accounts for more than 70% of total purines 
released; effects of the inhibitor can be expected to especially 
increase urate. 
Our experiments with infusion of the adenosine kinase inhibitor 
(5-iodotubercidin) indeed show an increased total normoxic purine 
release (Appendix Paper VI). The increase, however, is still very 
small. The inhibitor does not even double the control release and 
the effect is a fraction of the maximal adenosine kinase activity. 
This suggests that the adenosine-cycling hypothesis is not feasible 
in its originally proposed form. Then how is adenosine formation 
regulated? 
FIG. 6 ACETATE DEPENDENT INCREASE IN NORMOXIC PURINE RELEASE 
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Acetate infusion causes a dose-dependent increase in 
total purine release (~). Simultaneous infusion of an 
inhibitor of adenosine reincorporation (5-iodotubercidin, SITu) 
further enhances total purine release {c---D). Control release 
has been substracted. 
Increased AMP-formation is the simplest explanation. This is 
suggested by the fact that infusion of acetate gives a 
dose-dependent increase in purine release (Appendix Paper VI, 
Figure 6) . Acetate is rapidly taken up by the heart and transformed 
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into acetyl-CoA. Acetyl-CoA can be used as a substrate for 
mitochondrial ATP-formation. This "activation 11 of acetate requires 
ATP, and AMP (not ADP!) is formed. Acetate infusion results in 
increased myocardial AMP-levels (216) . Simultaneous infusion of 
acetate and iodotubercidin, however, gives an increase of purine 
release which is far more than additive (Appendix Paper VI). This 
shows that adenosine-cycling can occur and that it can be inhibited 
by iodotubercidin. 
We have already mentioned the fact that normal "free 11 
AMP-concentrations appear to be extremely low (preceding 
paragraph). In addition, adenylate kinase maintains the following 
equilibrium: 2 ADP~ATP + AMP. Because of the fact that the ratio 
ATP/AMP is normally very high, a small, barely detectable, change 
in ATP will result in a several-fold increase in AMP and adenosine 
formation (142) . The possible influence of high rates of fatty acid 
activation on adenosine formation explains the repeated findings of 
increased coronary flow during perfusion with fatty acids. 
Adenosine formation, therefore, is very tightly coupled to the 
equilibrium between formation and breakdown of ATP and to substrate 
use by the heart. 
The recent literature on the regulation of adenosine formation 
in the heart (B, 195) suggests that in physiological terms 
adenosine formation is regulated by the oxygen supply to demand 
ratio. In biochemical terms, however, adenosine formation is caused 
by increased AMP-formation (141) , either caused by a decreased 
ratio of ATP-formation over ATP-breakdown, increased breakdown of 
cyclic AMP or increased fatty acid activation. Especially the 
finding of increased purine release and vasodilation during acetate 
infusion (118, 197) appears to contradict the oxygen supply-demand 
hypothesis. 
3.7. Final conclusions 
For the quantification of purine release from isolated rat 
hearts it is essential to determine the formation rate of xanthine 
and urate. This is especially so during normoxia and mild ischemia 
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or hypoxia. This fact has recently been confirmed for guinea pig 
hearts, but applies to all species with myocardial xanthine 
oxidase/dehydrogenase activity, including man. The combined 
evidence that the enzyme responsible for urate formation is 
localized in the endothelium and that it can generate free radicals 
during reperfusion makes it necessary to study the role of the 
endothelium in the genesis of reperfusion damage and possibly 
atherosclerosis. 
FIG. 7 TIGHT COUPLING OF ADENOSINE- AND PURINE-FORMATION TO 
MYOCARDIAL ATP-TURNOVER 
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ATP-formation in the contractile compartment is depending 
mainly on creatine phosphate breakdown to creatine and partly on 
(anaerobic) breakdown of glucose to pyruvate. ATP-breakdown is 
mainly depending on contraction-related ATP-ase activity. 
Adenylate Kinase maintains the equilibrium between ATP, ADP and 
AMP. Increased AMP-levels will result in increased adenosine and 
purine formation. Both increased contractile activity 
(ATP-breakdown) and decreased ATP-formation will, at least 
temporarily, increase AMP-levels and adenosine formation. 
Adenosine formation is tightly coupled to substrate use, 
ATP-turnover and function of the heart and regulates coronary flow 
and oxygen supply. The increased formation of adenosine appears to 
be regulated by the myocardial AMP concentration (Figure 7) . 
The beneficial effects of stimulated net ATP-synthesis after 
ischemia by purines deserve much further attention, together with a 
31 
investigation of the relation between myocardial ATP, ADP, AMP and 
function of the heart under various conditions. 
A serious search for clinical applications of the accumulated 
knowledge of myocardial purine metabolism would appear to be 
unavoidable. 
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ENZYME ABBREVIATIONS AND ~OMENCLATURE 
Adenosi~e deaminase {ADA) 
Adenosine kinase 
(AK) 
Adenylate kinase (AdK) 
AMP-deaminase (AMP-D) 
Creatine kinase 
(CK) 
Hypoxanthine phosphoribosyl 
transferase {HPRT) 
Nucleoside phosphorylase 
(NP) 
5 1 -Nucleotidase 
(S'NT) 
Xanthine oxidase (XO) 
Xanthine dehydrogenase (XD) 
Adenosylhomocysteinase 
-Adenosine arninohydrolase {EC 3o5.4.4} 
-ATP~ adenosine s~-phosphotrans­
ferase (EC 2o 7 ol. 20) 
-A7P: AMP phosphotransferase 
(EC 2o7o4o3) 
-~MP aminohydrolase (EC 3.5.4.6) 
-ATP: creatine phosphotransferase 
(EC 2 o 7 o 3. 2) 
-IMP: pyrophosphate phosphoribosyl-
transferase (EC 2.4.3.8) 
-Purir.e-nucleoside: orthophosphate 
transferase (EC 2. 4. 2.1) 
-5'-Ribonucleotide phosphohydrolase 
(EC 3 o 1 o 3 . 5) 
-Xanthine: oxygen oxidoreductase 
(EC 1.2o3o2) 
-Xanthine: NAD oxidoreductase 
(EC 1.2.1.37) 
-S-Adenosyl-L-homocysteine hydrolase 
(EC 3.3.1.1) 
49 

SAMENVATTING 
Adenosine, een potente coronaire vaatverwijder, is een 
afbraakprodukt van het energierijke fosfaat ATP. ATP fungeert in 
het hart als de directe energiebron voor de contractie. Hoofdstuk 1 
van dit proefschrift geeft een korte algemene inleiding over 
ATP-afbraak in relatie tot contractie, over het metabolisme dat de 
ATP-vorming verzorgt en over het mechanisme van adenosine vorming. 
De toepassingen, die de biochemie van de purines heeft voor 
cardiovasculair onderzoek, worden kart samengevat. 
In Hoofdstuk 2 wordt de voornaamste literatuur samengevat, 
aangaande de rol van adenosine bij de regulatie van de coronaire 
vaatverwijding. Tevens worden de anticatecholaminerge effecten van 
adenosine besproken en de invloed van adenosine op de 
electrornechanische activiteit van het hart (2.1-2.3). 
Het rnetabolisme van adenosine, adenine nucleotiden en verwante 
purines wordt samengevat (2.4) met de nadruk op klinische 
toepassingen voor diagnostische en therapeutische doeleinden. Het 
potentieel gebruik van purines voor secundaire preventie in de 
cardiologische kliniek wordt besproken vanuit de experimentele 
aanwijzingen uit de literatuur. 
Er zijn veel aanwijzingen dat er een directe relatie bestaat tussen 
de uitwas van adenosine en purines tijdens ischemie, het 
post-ischemisch ATP-gehalte en de functie van het hart (2.5). 
Het experimentele gedeelte (Hoofdstuk 3 en de Appendix Papers) 
geeft meer gedetailleerde informatie over het purine rnetabolisme in 
geisoleerde, geperfundeerde ratteharten onder normoxische en 
ischemische condities. 
wanneer adenosine in rnicromolaire concentratie wordt geinfundeerd 
in geisoleerde harten wordt een gedeelte (15-20%) opgenomen door 
het hart. Adenosine wordt echter voornamelijk gedeamineerd tot 
inosine, dat verder wordt afgebroken tot hypoxanthine, xanthine en 
uraat. Uraat is de voornaarnste purineverbinding die uit het 
normoxische hart vrijkomt. De maxirnale activiteit, gemeten in hart 
homogenaten, van het enzym dat uraat vorrnt (xanthine 
oxydase/dehydrogenase) komt goed overeen met de maxirnale vorming 
van xanthine en uraat in geisoleerde, ischemische harten. Een 
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gedeelte van dit enzym is aanwezig in de oxydase vorm en kan vrije 
radicalen vormen, die het hart irreversibel kunnen beschadigen. 
De in vitro eigenschappen van andere enzymen van het purine 
metabolisme (AMP-deaminase en S-adenosylhomocysteine hydrolase) 
worden beschreven. Aanvullende perfusiestudies met specifieke 
remmers suggereren dat deze enzymen in belangrijke mate bijdragen 
aan de normoxische purinevorming (Appendix Papers II en IV) . 
Er zijn een aantal aanwijzingen dat de purines die in het hart 
gevormd worden voor een deel afbraakprodukten zijn van IMP of 
GNP; en niet van AMP. Dit lijkt in het bijzonder zo te zijn 
tijdens normoxie. 
Wanneer hypoxanthine of inosine aan het perfusaat van het hart 
worden toegevoegd, worden ze langzaam in de ATP-voorraad van het 
hart ingebouwd. Deze inbouw is sneller na een voorafgaande periode 
van ischemie en kan verder gestimuleerd worden door gelijkti~dig 
infuus van ribose. 
Er zijn aanwijzingen gevonden, dat versnelde adenosine vorming 
in het hart direct gerelateerd is aan de vorming van AMP (b.v. uit 
ATP/ • De oude hypothese dat adenosine constant met hoge snelheid 
geproduceerd wordt en onmiddellijk weer wordt gefosforyleerd tot 
AMP blijkt onrealistisch. De resultaten tonen aan dat de koppeling 
van adenosine- en purinevorming met de energiebalans van het hart 
sterker is dan werd aangenomen. Een geringe verstoring van de 
balans tussen ATP-vorming en ATP-afbraak zal een verhoogd vrijkomen 
van adenosine en ander purines veroorzaken en zal uiteindelijk tot 
een aanzienlijk_ ATP-verlies en verlies van functie leiden. Sornrnige 
van de gerapporteerde experimenten suggereren een benadering die 
deze vicieuze cirkel kan doorbreken, omdat ze de condities 
aangeven, waaronder versnelde ATP-synthese en functieherstel 
mogelijk zijn. 
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UITLEG VOOR DE LEEK 
Het hart is een dikke spier die door samentrekken (kloppen) 
zorgt voor het pompen van zuurstofrijk bleed door het hele lichaam. 
De bloedvoorziening van de hartspier gaat via de kransslagaderen 
(coronairen) . Het voortdurend kloppen van het hart vergt veel 
energie, Deze energie wordt in de spiercellen van het hart gevormd 
uit voedingsstoffen (suikers, vetzuren) die met behulp van 
zuurstof, dat via het coronaire bleed wordt: aangevoerd 1 "verbrand" 
worden. 
De "verbranding" waarvan hier sprake is, is eigenlijk een 
stapsgewijze omzetting van stoffen door middel van specifieke 
eiwitten (enzymen), die ieder een stapje van de afbraak voor hun 
rekening nemen (stofwisseling). De energie die vrijkornt, wordt 
vastgelegd in bepaalde "energierijke" stoffen (ATP en creatine 
fosfaat). Andere, vezelachtige, eiwitten die in de hartcel aanwezig 
zijn, kunnen dit ATP gebruiken om samen te trekken. Als alle cellen 
gelijktijdig samentrekken (contractie), klopt bet hart. ATP is de 
"benzine" van bet hart, die helaas niet rechtstreeks aan bet hart 
toegediend kan worden, omdat ATP de celwand niet kan passeren. 
Als het hart sneller gaat kloppen (stress, inspanning), wordt 
er tijdelijk zoveel ATP afgebroken, dat bet zuurstofaanbod bij de 
normale doorstroming van de kransslagaders niet voldoende is. De 
afbraak van ATP is enige tijd sneller dan de aanmaak. Er kan dan 
een afbraakproduct van ATP uit het hart lekken (adenosine). Dit 
adenosine heeft een vaatverwijdende werking op de kransslagader, 
die daardoor meer bloed (en zuurstof) naar het hart kan voeren, 
zodat weer genoeg ATP gemaakt kan worden. Adenosine kan door 
verschillende eiwitten (enzymen) gemaakt worden. De afbraak van 
adenosine doorloopt op zijn beurt een aantal enzymatische stappen. 
Behalve adenosine lekken er bij zuurstoftekort dan ook een aantal 
andere afbraakprodukten van ATP (purines) uit bet geisoleerde 
rattehart, dat we als model gebruikt hebben. Door metingen van 
ATP en zijn afbraakprodukten ADP en AMP in het hartweefsel, en 
van adenosine en verdere afbraakprodukten in de vloeistof 
waarmee bet hart wordt doorstroomd, hebben we een betere indruk 
gekregen van de regeling van de aanmaak en afbraak van adenosine in 
het hart. Uit onze experirnenten kunnen we concluderen, dat de 
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vorming van adenosine zeer direct gekoppeld is aan het evenw~cht 
tussen de aanmaak en afbraak van ATP. Een vroegere hypotheser die 
een constante, snelle vorming en directe afbraak van adenosine 
suggereerde, lijkt onjuist. 
De door adenosine geregelde vaatverwijding in het hart is 
voornamelijk werkzaam in het min of meer "gezonde" hart, dat een 
verhoogde belasting te verduren heeft, bijvoorbeeld door stress, 
versnelde hartslag, verhoogde bloeddruk, licht zuurstoftekort. Een 
betere kennis van de stofwisseling van adenosine en ATP kan echter 
ook voor het "zieke" hart van belang zijn. Vernauwing van de 
kransslagader (atherosclerose, infarct) zal het zuurstofaanbod naar 
het hart sterk doen verminderen. Omdat dan meer ATP wordt 
afgebroken dan aangemaakt, zullen adenosine en zijn afbraak-
produkten uit het hart verdwijnen. Zelfs bij een hersteld 
zuurstofaanbod zal het ATP-gehalte uiteindelijk lager zijn dan 
normaal. Omdat een verlaagd ATP-gehalte vaak gepaard gaat met een 
verlaagde hartfunktie, wordt er naar methodes gezocht om het 
ATP-gehalte weer snel op peil te brengen. Dit zou tevens een 
gedeeltelijke bescherming kunnen bieden tegen een volgende periode 
van slechte doorbloeding van het hart. Sommige van de in dit 
proefschrift beschreven experimenten laten zien dat versneld op 
peil brengen van de ATP-voorraad van het hart inderdaad mogelijk 
is. 
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MYOCARDIAL XANTHINE OXIDASE/DEHYDROGENASE 
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High-energy phosphates in heart muscle deprived of oxygen are rapidly broken down to purine nudeosides 
and oxypurines. We studied the role of xanthine oxidase/dehydrogenase (EC 1.2.3.2/EC 1.2.1.37) in this 
process with novel high-pressure liquid chromatographic techniques. Under various conditions, including 
ischemia and anoxia, the isolated perfused rat heart released adenosine, inosine and hypoxanthine, and also 
substantial amounts of xanthine and urate. Allopurinol, an inhibitor of xanthine oxidase, greatly enhanced 
the release of hypoxanthine. From the purine release we calculated that the rat heart contained about 18 mU 
xanthine oxidase per g wet weight. Subsequently, we measured a xanthine oxidase activity of 9 mU j g wet 
'Wt. in rat-heart homogenate. When endogenous low molecular weight inhibitors were removed by gel 
filtration, the acthity increased to 31 mU j g wet w1. Rat myocardial xanthine oxidase seems to be present 
mainly in the dehydrogenase form, which upon storage at -20°C is converted to the oxidase form. 
Introduction 
During hypoxia, A TP in the heart is rapidly 
dephosphorylated, and adenosine and its catabo-
lites are released (for review, see Ref. 1). Adeno-
sine, inosine and hypoxanthine have been used as 
markers for ischemia in animals models [2-4] and 
in the clinical setting [5-7]. In these instances, 
hypoxanthine (and xanthine) were measured with 
an enzymological assay [8]. It had been assumed 
that hypoxanthine was the end-product of myo-
cardial adenosine metabolism [9], but recently the 
release of urate from the isolated rat heart has 
been reported [10]. With a novel high-pressure 
liquid chromatographic (HPLC) assay we are now 
able to distinguish between hypoxanthine, xanthine 
and urate and measure them simultaneously [II]. 
Data on rat myocardial xanthine oxidase activity 
(EC 1.2.3.2) in vitro are conflicting: some investi-
gators could not detect the enzyme [12,13] and 
others reported low activity [14,15]. 
Xanthine oxidase exists in mammals in two 
OJ66-3178j$03.00 10 1983 Elsevier Science Publishers B.V. 
forms [16,17]: a dehydrogenase (EC 1.2.1.37). 
which uses NAD+ as electron acceptor, and an 
oxidase, with 0 2 as the electron acceptor (18]. 
Upon storage, the dehydrogenase form is con-
verted to the oxidase form [18]. 
We assayed purine release from normoxic and 
ischemic/ anoxic perfused rat heart and estimated 
the xanthine oxidase activity from the production 
of the oxypurines. Furthermore, we measured the 
activity of both enzyme forms in homogenates. 
Part of this study have been published in ab-
stract form [19,20]. 
Materials and Methods 
Chemicals. All chemicals were analytical grade. 
Water was purified with the Milli-Ro4-Milli-Q 
system (Millipore, Bedford, MA, U.S.A.): pento-
barbital was purchased from Abbot, Saint Remy-
sur-Avre, France; [8- 14 C]xanthine (40-60 Cijmol) 
was obtained from ICN, Irvine, CA, U.S.A.; bovine 
serum albumin and dithiothreitol were bought from 
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Sigma. St. Louis, MO, U.S.A.; allopurinol (4-hy-
droxypyrazolo(3,4-d) pyrimidine) was purchased 
from :Burroughs-Wellcome, London, U.K.; the 
other purines were supplied by Boehringer Man-
nheim, F.R.G. 
Heart perfusion. The experiments were per-
formed with male Wistar rats (250-440 g), fed ad 
libitum. The animalS were anesthetized with 
pentobarbital and the hearts were excised arid 
arrested in ice-cold perfusion medium, a modified 
Tyrode solution containing glucose [21,22]. For 
our first set of experiments the working heart 
preparation [23] was used with a preload of 10 
cmH 20 and afterload of 75 cmH 20. For the in-
duction of ischemia, a one-way ball valve was 
placed in the aortic outflow tract [23]. In a second 
series ·of experiments the Langendorff preparation 
was used [22,24] with 100 cmH 20 perfusion pres~ 
sure. In this case hearts were made temporarily 
ischemic by reducing coronary flow with a roller 
pump [22], or anoxic by replacing oxygen in the 
perfusion liquid by nitrogen. The perfusion tem-
perature was 37°C. Apex displacement was mea-
sured as described earlier [2]. 
Myocardial homogenate. After 10 min of retro-
grade perfusion [22] to remove blood, rat hearts 
were cooled in 30 mM K 2 HP04/0.4 mM EDTA · 
Na 2 (pH 8.3) at 0°C, weighed and homogenized in 
6 ml of this buffer at ooc with a Virtis homo-
genizer (Virtis, Gardiner, NY, U.S.A.). Where in-
dicated, the buffer contained 1 mM dithiothreito!, 
which prevents conversion of xanthine dehydro-
genas'e to the oxidase form [25}. The homogenate 
was centrifuged at 1500 X g for 10 min and the 
supernatant fluid was used immediately, or stored 
at - 20°C. Just before the xanthine oxidase assay 
the homogenate was passed through a Sephadex 
G-25 column {PD-10. Pharmacia, Uppsala, 
Sweden) to remove low-molecular-weight com-
pounds including endogenous inhibitors [14]. 
Xanthine oxidase/ dehydrogenase assay. [8-
14C]Xanthine was purified by HPLC {see Ref. 11, 
but with 25 mM KH 2P04 (pH 6.0) as eluent). The 
assay conditions were 60 p.M [8- 14 C]xanthine (40 
mCijmol), 30 mM K 2 HP04, 0.4 mM EDTA · Na 2 
(pH 8.3), and heart homogenate diluted with I% 
bovine serum albumin to 0.5 ml (cf. Ref. 26). The 
final volume was 1.0 mi. Incubation took place at 
30°C for 60 min in the presence or absence of 0.1 
mM NAD.,.. The reaction was stopped with 0.2 ml 
20% HCJ04. After centrifugation, the supernatant 
fluid was brought to pH 4-7 with 0.1 ml 1.7 M 
K 3 P04, and the radioactive product and substrate 
were separated by HPLC (see Ref. 11, but with 50 
mM KH 2 P04 (pH 5.6)/3% v/v methanol). Flow 
rates up to 3 mljmin were used, and fractions of 
1.5 ml were collected and counted with 10 ml 
Instagel (Packard Inst., Downers Grove, IL. 
U.S.A.) in a Packard B460C liquid scintillation 
counter. Urate was identified by the enzymatic 
peak shift method with urate oxidase (EC 1.7.3.3). 
One unit (U) of enzyme activity corresponds to the 
formation of 1 p.mol product per min. 
Purine assay. The purine nucleosides and 
oxypurines in perfusates were assayed with HPLC 
as has been described before [11,12]. 
Statistical analysis. We used Student's t-test and 
considered P.;;;; 0.05 (two-sided) as a significant 
difference. Results are given as mean values± S.E. 
of the mean. 
Results 
Working heart 
Coronary flow was 69 ± 4 mlj min per g dry 
wt. during the control perfusion (Table I). Hearts 
were made severely ischemic with a ball valve in 
the aortic outflow tract. At the end of the ischemic 
period, coronary flow had decreased by 90% ( P < 
0.001), and aortic flow had ceased. The concentra-
tion of purine nucleosides and oxypurines in the 
coronary effluent had increased significantly, but 
due to the low flow the measured purine release 
had decreased to less than half the original value. 
Coronary and aortic flow recovered only partially 
when the constriction was removed. 10 min post-
ischemia, coronary flow was 35% of the control 
value ( P < 0.005). It is noteworthy that these 
working hearts released substantial amounts of 
xanthine (Table I), which could indicate the pres-
ence of xanthine oxidase in rat heart. 
Retrograde perfusion 
In one set of experiments, coronary flow was 
63 ± 5 ml/min per g dry wt. (Table II). In the 
effluents we also determined urate, which 
accounted for 74% of the purine nucleosides and 
oxypurines released during aerobic perfusion (Ta-
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TABLE I 
PRODUCTION OF PURINE NUCLEOSIDE$ AND OXYPURINES BY THE ISOLATED WORKING HEART 
Hearts were isolated from F1 hybrid rats from two inbred Wistar substrains. The perfused hearts were paced at 300 beatsjmin. At the 
end of 10-min periods of control perfusion, ischemia induced with a ball valve, or reperfusion, samples were taken for flow and purine 
measurements. Values are expressed (per g dry weight) as means±S.E. (n = 7). CF. coronary flow: AoF. aortic flow; Ado, adenosine: 
Ina, inosine; Hyp, hypoxanthine; Xan, xanthine. 
Condition Flow (mljmin per g) Production (nmoljmin per g) 
CF AoF Ado 
Control flow 69± 4 56±12 0.1 ±0.1 
Ischemia 7 ± 3. 0± 0" 3.6±2.3 
Reperfusion 24± 11" 9± 7' 5.9±2.0" 
• p..;;; 0.05 vs. control. 
ble II). Ischemia, induced with a pump, caused a 
reduction in coronary flow of 78% (P < 0.001). 
Apex displacement, a measure for contractility, 
decreased 68% (P < 0.001). Purine release 
increased considerably: the release of adenosine, 
inosine and (hypo)xanthine increased at least 10-
fold (Table II). However, urate production 
increased only 1.5-times, accounting for 18% of 
the purine nucleosides and oxypurines released 
during ischemia. During reperfusion, purine re-
lease decreased again. From the maximal release 
of xanthine and urate we calculated a rat-heart 
xanthine oxidase activity in situ of about 18 mU/g 
wet wt. at 37°C (during ischemia). 
Subsequently, we perfused rat hearts with 0.1 
mM allopurinol, an inhibitor of xanthine oxidase 
TABLE II 
Joo Hyp x,, 
23± 9 16±7 56±20 
19± 9 5±3 13± 7 
61±23" 17±6 32± 8 
[27]. In this experiment coronary flow increased 
more than twice due to 10 min of anoxia in the 
presence or absence of allOpurinol (P < 0.001). 
Under both conditions, the anoxia-induced 
decreases in apex displacement and in heart rate 
were 97% (P < 0.001) and 70~85% (P < 0.02), re-
spectively. H:ypoxanthine release increased from 
3 ± 1 to 70 ± II nmoljmin per g dry wt. due to 
anoxia (P < 0.001, Fig. 1). Reoxygenation caused 
the release to decrease to 13 ± 6 nmolj min per g 
dry wt. (P < 0.001 vs. anoxic value). We were 
unable to measure xanthine and urate in per-
fusates containing allopurinol due to interference 
of the drug in our HPLC assay. However, al-
lopurinol augmented h:ypoxanthine release. After 
I 0 min of normoxia, anoxia and reoxygenation the 
PRODUCTION OF PURINE NUCLEOSIDE$ AND OXYPURINES BY THE ISOLATED NON-WORKING RAT HEART 
Isolated perfused rat hearts were paced at 360 beatj:nin. After 20 min of aerobic perfusion, ischemia (induced with a roller pump) 
and reperfusion took place for 20 and 15 min. respectively. Measurements were made during the last 5 min of each period. Data are 
expressed as means±S.E. with the number of experiments in parentheses. Coronary flow and purine release are expressed per g dry 
weight; apex displacement is given relative to the value after 5 min of aerot.i<: perfusion. Ado. adenosine; !no, inosine; Hyp, 
hypoxanthine; Xan, xanthine; UA, urate. 
Condition Coronary 
flow 
(mljmin per g) 
Control flow (10) 63 ±5 
Ischemia (6) 14±1" 
Reperfusion (3) 47 ±8 b 
" P < 0.05 vs. control; 
b p < 0.05 vs. ischemia. 
Apex 
displacement 
(%) 
(100) 
32± 7" 
39±20" 
Production (nmoljmin per g) 
Ado 
'"" 
0.2± 0.2 4.2± OS 
38 ± 19" 83 ± 11 a 
± 6 22 ± 18 b 
Hyp Xoo UA 
2.3 ±0.5 1.1 ±0.4 22± 
23 ±6 l7 ±4" 36± 2' 
5 ±4 5 ±l 29± 12 
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Fig. I. Inhibition of hypoxanthine conversion by allopurinol in 
the retrogradely perfused heart. Hearts were isolated from F 1 
hybrid rats from two inbred Wistar substrains. Hypoxanthine 
release in the presence (8), or absence (0) of 0.1 mM al-
lopurinol is shown. Vertical bars denote S.E. ( n = 6-7). (A) 
P < 0.05 vs. normoxia (I= 9 min), (A) P < 0.05 vs. anoxia 
(t = 19 min). Hypoxanthine release in the presence of al-
lopurinol was higher during normoxia, anoxia and reoxygena-
tion (P < 0.05). dwt, dry weight. 
increase was 460% (P < 0.005, 64% (P < 0.001), 
and 420% (P < 0.002), respectively, of the value 
without the drug (Fig. 1). This indicates that, 
indeed, xanthine oxidase/dehydrogenase plays a 
role in the breakdown of hypoxanthine. 
Xanthine oxidase/ dehydrogenase in heart homo-
genate 
The conversion of xanthine to urate by 12 mg 
fresh homogenate, which formed 6 nmol urate per 
h, was linear for 4 h. In our assay urate production 
by different amounts of heart tissue was linear 
until 20 nmol urate had been formed. The pres-
ence of xanthine dehydrogenase was demonstrated 
when NAD+ was added to a fresh homogenate. 
The oxidase plus dehydrogenase activity was linear 
with urate production until 13 nmol urate had 
been formed in 1 h (Fig. 2). 
The xanthine oxidase activity found in heart 
homogenate depended on the treatment of the 
preparation. Removal of small molecules by gel 
filtration of the homogenate caused an increase in 
xanthine oxidase activity from 9 to 31 mU/g wet 
wt. and from 10 to 27 mUjg wet wt. at 30°C for 
xanthine oxidase plus dehydrogenase activity. In a 
"" 
;o 
' 
'" 
~ 
'" 
mg wwt heart tissue 
Fig. 2. Urate produced in 1 h by various amounts of rat heart 
xanthine oxidase/dehydrogenase. The activity was assayed with 
[8- 14 C]xanthine, 0 2 and NAD+. Substrate and product were 
separated by HPLC and counted in a liquid scintillation coun-
ter. Data are means± S.E. (n = 3). wwt, wet weight. 
fresh homogenate, the xanthine oxidase activity 
was low, about 7 mU/g wet wt.; addition of 
NAD+ stimulated 4-fold (Table III). Homogeni-
zation with dithiothreitol did not significantly in-
fluence the oxidase activity (Table III). After stor-
age at -20°C, xanthine oxidase activity was high 
(31 mUjg wet wt.), and NAD+-addition did not 
stimulate the activity (Table III). Allopurinol (0.1 
mM) inhibited the xanthine oxidase and dehydro-
genase activities by more than 98%. 
TABLE III 
XANTHINE OXIDASE AND DEHYDROGENASE ACTIV-
ITIES IN RAT HEART HOMOGENATE 
Perfused rat hearts were homogenized (with dithiothreitol where 
indicated) and centrifuged. The supernatant fluids were passed 
through a Sephadex G-25 column. With [8- 1 ~C]xanthine at 
30°C xanthine oxidase was assayed with 0 2 (air) and xanthine 
oxidasejdehydrogenasewith 0 2 and NAD ..... The enzyme activ-
ities are given as means± S.E. ( n ). 
Preparation 
Fresh 
Fresh +dithiothreitol 
Stored -20°C, 3d 
• P < 0.001 vs. stored; 
Activity (mU/g wet wt.) 
Xanth.ine 
oxidase 
6.6±0.4(6)"·~ 
5.3±0.5 (4)"·b 
31.3±2.8 (10) 
Xanthine oxidase 
plus xanthine 
dehydrogenase 
27.0±0.8 (4) 
27.8±1.4{4) 
33.1 ±2.6 (3) 
0 P < 0.001 vs. xanthine oxidase plus xanthine dehydrogenase. 
Discussion 
In a recent study on the degradation of ATP 
and its catabolites by the perfused rat heart, urate 
was found [10]. We observed that the anoxic and 
ischemic rat heart released substantial amounts of 
purine nucleosides and oxypurines including 
xanthine and urate. In the presence of allopurinol 
the release of hypoxanthine was much higher, so it 
seemed likely that xanthine oxidase was active in 
the isolated perfused rat heart, where it may play 
an essential role in the purine metabolism. Indeed. 
the direct assay of heart homogenates revealed 
xanthine oxidase activity, with a lower activity in 
fresh homogenates than in stored preparations. 
The difference could be accounted for by the 
presence of xanthine dehydrogenase activity. When 
NAD+ was added, xanthine dehydrogenase activ-
ity could be demonstrated in fresh homogenates 
only. In the presence of NAD+, urate production 
was inhibited during the course of the reaction. 
This is probably due to the accumulation of NADH 
which causes a feedback inhibition of xanthine 
dehydrogenase [28]. This mechanism may play a 
role in a purine salvage mechanism by reducing 
the breakdown of hypoxanthine [29] during 
ischemia when the concentration of this substrate 
for xanthine oxidase is high. The disappearance of 
NAD--stimulated urate production upon storage 
of heart tissue can be explained by the conversion 
of xanthine dehydrogenase to the oxidase form, as 
has been found for the liver enzyme [28]. In rat 
heart, Battelli et al. [16] could detect the dehydro-
genase form only after treatment of the homo-
genate with dithioerythritol, while we found 
xanthine dehydrogenase activity in untreated ho-
mogenates. This different finding may be ex-
plained by assuming the presence of sulfhydryl 
oxidase in rat heart. The enzyme catalyzes the 
conversion of xanthine dehydrogenase to the 
oxidase form [30]. EDT A (present in our homo-
genization buffer) inhibits sulfhydryl oxidase [31]. 
Krenitsky et al. [17], who also used EDTA during 
homogenization, found xanthine dehydrogenase 
activities in many mammalian tissues without spe-
cial treatment. Therefore. it seems important to 
include EDTA in the homogenization buffer if 
xanthine dehydrogenase activities are to be de-
tected. However, in our study EDTA did not 
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protect against conversion during storage at 
-20°C. Maybe this conversion is caused by a 
(slow) non-enzymatic oxidation of sulfhydryl 
groups by 0 2 . 
Myocardial xanthine oxidase activity has also 
been reported [17,32,33] for cat, dog, sheep, cow, 
man and mouse. The presence of a dehydrogenase 
form and inhibition by endogenous small mole-
cules, causing a low xanthine oxidase activity, may 
lead to false negative results as reported by Gandhi 
et al. [13] for rat heart. These problems may be 
avoided by using gel filtration [14] and NAD+ or 
Methylene blue [15], an electron acceptor for both 
enzyme forms, giving a higher total activity [18]. 
When hearts are homogenized in the presence of 
EDTA and dithiothreitol, there still is xanthine 
oxidase activity. This may represent a xanthine 
oxidase with different catalytic properties com-
pared to the dehydrogenase-derived oxidase, as 
has been found in mouse intestines [34]. 
We conclude that rat heart contains mainly 
xanthine dehydrogenase, which upon storage is 
converted to xanthine oxidase. The maximal activ-
ities calculated from xanthine and urate produc-
tion in perfused rat hearts are comparable with the 
xanthine dehydrogenase values found in homo-
genates. 
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Abstract--!. Cytosol from pig skeletal muscle. but not heart. contains an inhibitor of A\1P-deaminase 
(AMP-D. EC 3.5.4.6) which reduces AMP-D activity 8-fold. 
2. Heart and skeletal muscle AMP-D have been purified to apparent homogeneity by cellulose 
phosphate and DEAE-Sephacel chromatography. 
3. AMP-D from skeletal muscle is inhibited more severely than the heart enzyme by an increase in 
adenylate energy charge to levels exceeding 0.4. Nevertheless both enzymes seem to be regulated by the 
energy charge, which contrasts with reports for rabbit heart AMP-D. 
11\TRODUCTI0:'\1 
AMP-deaminase (AMP-D. EC 3.5.4.6) catalyzes the 
hydrolytic deamination of AMP to IMP and NH3 . 
The enzyme seems important in the regulation of the 
adeny1ate energy charge (ATP + 0.5 ADPJ... 
(ATP + ADP + AMP) and the adenine nucleotide 
pool, together with 5'-nucleotidase (EC 3. 1.3.5) and 
adenylate kinase {EC 2.7.4.3) {see review: De Jong. 
1979). Relatively little is known about AMP-D in 
heart. In view of the presence of tissue specific iso-
zymes of AMP-D (Ogasawara eta/.. 1978; 1982), it 
seems likely that the physiological role of this enzyme 
may vary from tissue to tissue. 
AMP-D has been purified to homogeneity from 
skeletal muscle of rabbit (Smiley et a/., 1967; Stan-
kiewicz et a/.. 1979), rat (Coffee & Koike, 1975; 
Ranieri-Raggi and Raggi, 1976; Ogasawara et a/.. 
1978; Shiraki et al.. 1979; Stankiewicz et al.. 1979) and 
man (Stankiewicz, 1981; Ogasawara eta/., 1982). The 
heart enzyme has been purified only partially from a 
number of mammalian sources: rabbit (Chung & 
Bridger, 1976; Solano & Coffee. 1978; Barsacchi eta/., 
1979), rat (Ogasawara eta/.. 1975; Kaletha & Sklada-
nowski, 1979). pig (Purzycka-Preis et al.. 1978), beef 
{Skladanowski eta/., 1981) and man (Kaletha eta/., 
1979; Ogasawara eta/.. 1982). Because of our interest 
in pig purine metabolism (De J ong & Goldstein, 
1974; DeJong et al., 1977) we decided to purify por-
cine heart and skeletal muscle AMP-D to homogen-
eity and studied the response of the enzymes to 
various adenylate energy charges*. 
MATERIALS A:'\10 METHODS 
Nuclwtides 
These were purchased from Boehringer. Mannheim, 
GFR. 
*Part of this study has been presented at the 4th Inter-
national Symposium on Human Purine and Pyrimidine 
Metabolism. Maastricht. The Netherlands (Verwoerd eta/.. 
1982). 
AMP-D assay {see Smiley el a/., !967) 
The enzyme was incubated at 30'C with 50 mM imida-
zole. HCL 20 mM sodium cacodylate. 0.5 M KCl. l :nM 
2-mercaptoethanol and 5 mM 5'-AMP (except for the ex-
periments shown in Fig. 1). The pH l'.'as 6.5 and the final 
volume LO ml. IMP formation was detected at 285 nm •.vith 
a Gilford 2600 spectrophotometer (Gilford, Oberlin. OH). 
Protein determination 
The Coomassie Brilliant Blue (Biorad Laboratories. 
Munich, GFRl assay was used with bovine serum albumin 
(Sigma, St. Louis. MOl as the standard. 
Purification of AMP-D (see Coffee & Kofke, 1975: Pur-
zycka-Preis eta/., 1978) 
Each buffer contained l mM 2-mercaptoethanol. All 
steps were performed at 0-5 'C. Heart or white ske~etal 
muscle (100 g) from piglets (S~1.1 scrofa. about 25 kg) was 
homogenized with 3 vol (v./w) of 0.18 M KCl-0.054 M 
KH 2P04 -0.035 M K 2 HP04 (pH 6.51. The homogenate 
was centrifuged for 30 min at 25,000 g. and the supernatant 
fluid passed through Nuova filter material (Hoffmann, 
Overath-Eulenthal. GFR). The eluate was stirred with 
30 ml washed cellulose phosphate Pll (Whatman. Maid-
stone, UK; 5 g) for 1 hr. The slurry was then transferred to 
a glass column (1.5 x 12cm) and washed with the extrac-
tion buffer until the effluent had an absorbance at 280 nm 
below 0.01. The enzyme was eluted with 1M KCl (pH 6.5). 
Fractions with the highest specific activity were pooled and 
dialyzed against 0.045 M potassium phosphate (pH 7.2) 
The dialyzate was applied to a DEAE--Sephacel cobmn 
(Pharmacia, Uppsala. Sweden; !.5 x 15 em). which had 
been equilibrated with this phosphate buffer. and \.\'ashed 
with lOOm! buffer. The enzyme was eluted with a linear 
gradient consisting of l 00 ml each of 0.045 and 0.45 \1 
potassium phosphate {pH 7.2). 
Ge1Jerarion of energy charge ratio-> 
AMP and ATP were incubated with adenylate kinase as 
described by Coffee & Solano (1977). The concentrations of 
AMP, ADP and ATP were determined by high perform-
ance liquid chromatography (Harmsen e/ a/., 1982). The 
individual nucleotide concentrations were found to be 
within 10'/;, of the calculated ones 
2 E. HAR\1SEl' l'l (i/. 
Table I. AMP~deaminase activity (U/mg protein) of plg 
heart and skeletal muscle cytosol 
Tr·~atment 
None 
Gel fUration 
Heart 
0.099 ± 0.006 
0.104 ± 0.010 
Skeldal mu~cle 
0.340 ± 0.018~t 
2.74 ± 0.038* 
Mean values of 3 to 4 experiments ± SEM Students 
r-test: *P < 0.001 vs heart. tP < 0.001 vs treatment with 
Sephadex G-25 gel. 
RESULTS 
Actiuity 
Table 1 shows that the activity of AMP-D in the 
cytosol of skeletal muscle could be increased 8-fold 
(to 2.7 U/mg protein) by removal of endogenous in-
hibitors. This treatment did not influence the heart 
enzyme, \Vhich had an activity of 0.10 Ujmg protein. 
Purification 
In Table 2 data of the purification of AMP-D from 
heart and skeletal muscle are presented. With cellu-
lose phosphate and DEAE-Sephacel chromatography 
they were purified 426 and 526 times. respectively. 
Disc electrophoresis on polyacrylamide (10% acryl-
amide, plus sodium dodecylsulfate) gave only one 
band. The cardiac enzyme did not show 5'-nucleoti-
dase or adenosine deaminase (EC 3.5.4.4) activity. It 
was quite labile: 10/,, of enzymic activity disappeared 
when the preparation was kept overnight at -20'C. 
Repeated freeze-thawing caused the activity to disap-
pear completely. Purified skeletal muscle AMP, on 
the other hand, remained active. when treated Ji:.:.e 
this. 
Properties of the purified enzymes 
The apparent Km of purified heart and skeletal 
muscle AMP-D was 3.8 and 1.2 mM, respectively. The 
Hill constant, nfi. was comparable for the two 
enzy:nes: 1.0 (heart AMP-D) and 1.1 (skeletal muscle 
AMP-D) 
Effect of energx charge 
Skeletal muscle AMP-D was inhibited by increas-
ing adenylate energy charge (Fig. I). Heart AMP-D 
showed a biphasic response. At energy charges which 
are probably physiological (>0.5), skeletal muscle 
AMP-D is inhibited 1.5-2.7 times more than heart 
AMP-D. The effects were most pronounced at lower 
(5 mM) total adenine nucleotide pool sizes. 
DISCUSSIO"J 
The activity of AMP-Din pig skeletal muscle cyto-
sol increased 8-fold. when low molecular weight com-
ponents were removed (Table 1). It is of interest that 
Fishbein eta/. (1981) found a specific inhibition of 
muscle AMP-Din serum and plasma of humans and 
animals. Apparently pig heart cytosol did not contain 
inhibitors v.'hich could be removed by gel filtration 
(Table l). The Vm,, is 25 times lower than that in 
skeletal muscle cytosol (after gel filtration). Ogasaw-
ara et ol. (1982) did a similar observation in human 
tissues. 
Skeletal muscle AMP-D has been purified to hom-
ogeneity from a variety of species. However. the heart 
enzyme has only been completely purified from duck 
(Pekkel' and Kirker, 1979), but not from the mam-
malian heart. Purzycka-Preis er a/. (1978) obtained 
AMP-D from porcine heart by cellulose phosphate 
chromatography, but their preparation was presum-
ably impure. We found it necessary to use DEAE-
Sephacel chromatography after the cellulose phos-
phate step to obtain an apparently homogeneous 
preparation. Our procedure is considerably simpler 
than the one used by Pekkel' & Kirker (1979). 
Purzycka-Preis eta/. (1978) found a half-saturating 
substrate concentration for porcine heart AMP-D of 
5 mM. This is comparable to our value (3.8 mM). For 
pig skeletal muscle AMP-D we found the K,., to be 
3-fold lower. This contrasts findings by Ogasawara et 
a/. (1975) who reported that rat skeletal muscle 
AMP-D has a K, which is 3--4 times higher than that 
of heart. 
Purzycka-Preis er a/. (1978) reported cooperative 
binding of AMP for pig heart AMP-D (nH = 2.35). 
This value decreased to about 1 on addition of A TP 
and liposomes. In our hands nH = 0.96 was found for 
the purified enzyme without any addition, which is 
similar to the value reported for rat heart AMP-D 
(Kaletha & Skladanowski, 1979). We conclude from 
our studies that the number of binding-sites for AMP 
on AMP-D from pig heart and skeletal muscle is the 
same. 
Solano & Coffee (1978) reported that rabbit heart 
AMP-D was unaffected by energy charges below 0.9, 
in contrast to the skeletal muscle enzyme which in-
creased gradually in activity when the energy charge 
was decreased from 1.0 to 0. We observed that pig 
skeletal muscle enzyme AMP-D behaved comparably 
to that from rabbit (Fig. I). Although the inhibition 
observed with physiological energy charges Wi1S less 
for the heart enzyme (Fig. 1), AMP-D from porcine 
heart seems to be regulated by the energy charge. 
whereas rabbit heart AMP-D always seems to be in 
Table 2. Purification of pig heat and skeletal muscle AMP-deaminasc 
Purification step 
Supernatant fluid 
Cellulose phosphate 
DEAE-Sephllcel 
SM. skeletal muscle. 
Specific activity 
(C,img protein) 
Heart SM 
0.10 
20 
30 
0.30 
75 
!56 
Purilicution 
('I 
Heart SM 
(I) (I) 
208 252 
426 526 
Yield 
(/;',) 
Heart SM 
(100) (100) 
20 62 
II 42 
Porcine heart and skeletal muscle regulation 
5 mM nucleotides 10 mM nucleotides 20 mM nucleotides 
100 100 
" 
0 
50 
1 
~ 0 
0.5 1.0 0._5 1.0 0 0.5 1.0 
energy charge energy charge energy charge 
Fig. !. Response of AMP-D to variation in the adenylate energy charge lit different total adenine 
nucleotide pool sizes. Purified enzyme of pig skeletal muscle (SM. 3 11g} and heart (H. 10 /lg) were test.:d 
in triplicate. Maximal <tctivities (flmol.imin) observed at 5 mM nucleotides: 0.39 (SM) and 0.12 (H); at 
10 m\1 nucleotides: 0.53 (SM) <>nd 0.30 (H): at 20 mM nucleotides: 0.49 (SM} and 0.38 {H). 
the activated state (Solano & Coffee. 1978; Barsacchi 
era/., 1979). 
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Enhanced ATP and GTP synthesis from hypoxanthine 
or inosine after myocardial ischemia 
EEF HARMSEN, PETER P. DE TOMBE, JAN WILLEM DE JOJ\'G, 
AND PETER \V. ACHTERBERG 
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HAR:.ISEN, EEl<', PET£R P. DE TOI>1BE. ,JA:'-1 W!LLEM D£ 
.)ONG, AND PETER W. ACHTERBERG. Enhanced .4 TP and CJTP 
,,ynthe~i.s from hypoxanthine or ino8me after myocardial is-
chemia. Am. ,J. PhysioL :246 (Heart Circ. Physiol. 15): H:J7-
H4:l, 1984.-lncreasinr:: therapeutic use is made of purines :·or 
the treatment of ischemic heart disease, but little is known 
about regulatorv mechanisms involved. Therefore we perfused 
isolated rat he3.rts with 0.0:2 mmol/1 [S·''C]hypoxanthine or 
inosine. Under normoxic conditions abom 1% is taken up h) 
the heart and partially used for synthesis of ATP and GTP at 
a rate of 0.4 and 0.1 nmol· min-'. g dry we', respectively. After 
relatively mild ischemia (coronary flow reduction of70% for 20 
min}. no increase in myocardial purine uptake is observed. but 
ATP and GTP synthesis rates are doubled (P < 0.001}. D· 
Ribose stimulates the hypoxanthine incorporation rate in nor-
moxie perfused rat hearts to 1.1 and 0.5 nmol-min-'.g dry >vt- 1 
for ATP and GTP, respectively. which is further increased 
during postischemic perfusion. About SO% of the [8-' 'C]inosine 
or [8-''C]hypoxanthine passes through the heart unchanged, 
while 1.5% is converted to (hypo}xanthine and uric acid. We 
conclude from these experiments that inosine and hypoxan-
thine incorporation into ATP and GTP is at least partly 
regulated by the availability of 6-phosphoribosyl-l-pyrophos-
phate. 
nudeolide biosynthesis; salvage: oxypurine; nucleoside; ribose; 
heart: rat 
!N THE AEROBIC HEART a critical balance exists between 
production of ATP and its utilization. If the heart be-
comes ischemic, this delicate balance is disturbed, and 
energy·-rich phosphates are broken down to the nucleo-
sides and purine bases adenosine, inosine, hypoxanthine, 
xanthine, and uric acid. These apolar compounds can 
pass the cellular membrane and enter the bloodstream 
(2, 9). Because of this loss of purines, ATP levels will 
remain below control levels after reoxygenation (see, e.g., 
Ref. 18). To restore these adenine nucleotide pools three 
main pathways exist (Fig. 1}. 1) In adenosine phospho-
rylation, adenosine is directly phosphorylated to AMP 
by adenosine kinase. The maximal incorporation rate in 
rat heart amounts to about 50 nmol-min- 1 ·g dry ,,,-:- 1 
(16). This pathway is energetically economical. However, 
the adenosine concentration in blood is low, and this 
could be a restricting factor for adenosine phosphoryla-
tion. 2) In hypoxanthine salvage, hypoxanthine can be 
phosphorylated with 5-phosphoribosyl-1-pyrophosphate 
(PRPP) to form IMP (5, 12, 14, 22). IMP is a crucial 
branching point between adenine and guanine nucleotide 
synthesis. In rat heart the hypoxanthine incorporation 
rate into ATP can amount to :3 nmol- min- 1 • g dry wt- 1 
(14} . .'3} In de novo synthesis. purine nucleotides (adenine 
and guanine nucleotides} are also synthesized from small 
precursor molecules (among others, glycine, CO~). In a 
10-step synthesis from PRPP, IMP is formed. De novo 
production rate of IMP in rat heart is about 0.1 nmol-
min-1-g dry wC1 ("24}. This process is stimulated after 
anoxia, ischemia, and hypertrophy. As an explanation 
for this phenomenon, an enhanced synthesis of PRPP 
by acceleration of the hexose-monophosphate shunt has 
been proposed (24). To bypass this shunt. ribose (a 
precursor of PRPP) can also be supplied (2.'i). 
We decided to study the incorporation of [8- 1-'C]hy-
poxanthine into normoxic or postischemic rat hearts in 
the presence of D -ribose to investigate whether hyl)oxan-
thine incorporation is also PRPP dependent. Because 
inosine, a precursor of hypoxanthine, is used as a cardi-
oprotective and vasodilatory agent (4, 10, 11, 21, 23), [8-
'-'C]inosine incorporation rates in aerobic and postische-
mic rat hearts were also determined. Mammalian cells 
lack inosine kinase (22}; therefore inosine is converted 
to hypoxanthine and ribose-1-phosphate. Subsequently, 
part of the hyl)Oxanthine is converted to IMP; ribo;:,e-1-
phosphate can serve as a precursor of PRPP. 
Hypoxanthine and inosine are incorporated not only 
into adenine nucleotides but also into guanine nucleo-
tides. To our knowledge no data about purine incorpo-
ration into myocardial guanine nucleotides have been 
published, although Swain et a!. {20) recently investi-
gated the incorporation of .'i-aminoimidazol-4-carbox-
amide riboside (AI CAR, an intermediate of the de novo 
pathway} in dog heart and found repletion of ATP and 
GTP levels. 
:V!ATERIALS AND METHODS 
Perfusion protocol. Male Wistar rats [315 ± 34 (SD) 
g] were used. Hearts were removed and perfused as 
described earlier {3). The basic perfusion buffer (pH 7.4} 
consisted of {in mM} KaCl 125, KC! 4.7, CaCb L35. 
!\'aHCO:l 20, NaH~PO., 0.4, :VlgCb 1.0, and o-glucose 10 
and was equilibrated with 35% 0~-5% C02• The perfusion 
pressure was 72 mmHg. meawred with a Statham pres-
sure transducer (model P2:306, Gould, Oxnard, CA}. The 
hearts were paced at 300 beats/min. and the temperature 
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FJG. 1. Biosynthesis of ATP ~nd GTP. Pathway 1. adenosine pho8-
phorylatiun; palh1wy 2, hypoxanthine ealvag-e: pathway .:J, de 110\'0 
synthesis. ADA, adenosine deaminase fEC :J.S.4.4): ADO. adenosine: 
AK. adenosine kinase (EC ~.7.1.20). AI'\'lPS. adenylosuccinate: HPHT, 
was :n.o ± O.!'i'C. 
The hearts were equilibrated with the buffer for 20 
min (period 1: aerobic perfusion). Then global ischemia 
was induced with a roller pump at a fixed flow of 2.6 ml/ 
min (flow reduction by 65-i.'3%) for 20 min (period 2: 
ischemia), followed by 5 min of reperfusion (period 3: 
reactive hyperemia). Hereafter perfusion took place for 
an additional 15 min (period 4: reperfusion) with 0.02 
mM [8- 1-'C]hypoxanthine. 0.02 mM [8- 14 C]inosine, or 
0.02 mM [8- 1'1C]hypoxanthine + 0 .. 5 mM ribose (all dis-
solved in the perfUsion fluid, radioactivity 5 J.ICi/1). After 
period 1, hearts were perfused with basic perfusion me-
dium for I min to wash out the labeled substrates from 
the blood vessels. In the control group no ischemia was 
induced during period 2. 
Chemicalr;. All chemicals were analytic grade. \Vater 
was purified with the Milli-Ro4/Milli-Q system (Milli-
pore, Bedford. MA). [8- 14C]hypoxanthine and [8- 1"1C] 
inosine were supplied by Radiochemical Centre (Amer-
sham, Bucks., UK; sp act 60-60 Ci/mol, diluted to 0.25 
Ci/mol before use). 
Anal;1tic methods. Samples were collected and stored 
on ice until analysis. No changes in purine composition 
of the perfusates were seen within the storage period, 
which was 12 hat the most. Adenosine(catabolites) \Vere 
assayed by a slightly modified version of the high-per-
formance liquid chromatography (HPLC) method de-
scribed by Harmsen et al. (6). A ~-tBondapak C1_. column 
(\Vaters Associates, Milford, .\IIA) was eluted at a flow 
rate of 3.0 ml/min \v·ith ';5 mM KH2P04, pH 4.50, to 
which methanol (30 ml/ll haci been added. Two hundred 
microliters of the coronary effluent were injected on the 
h_vpoxnnthint phosphoribowltmnsi"era"e iEC 2.4.2.51: I!\0. inosine: 
.'IP. purine-nucleoside pho~phoryJa.,e iEC 2.4.2.1 1: PP., pyrophosphate: 
PRPP. phosphoribosyl pyrophosphate: l"A. uric a~id: XAK. xanthine: 
Xlvlf'. xanthine-~' -monopho<phate: XO. xanthine oxidase IEC 1.2.:1.21. 
sy'stem. Peab were integrated {Varian CDS-111, Varian. 
Palo Alto, CA) and compared with standards. From 
radioactive samples the various HPLC peaks were col-
lected. Ten milliliters of Instagel (Packard Instruments, 
Downers Grove, ILl were added, and radioactivitv was 
determined with a Packard Tricarb 2650 liquid sCintil-
lation counter. 
The perfusion experiment was terminated by freeze 
clamping the heart between two aluminum blocks pre-
cooled in liquid N.; {-190'C). After being weighed, the 
heart was ground in a mortar, and about 0.:3 g was mixed 
with :3.0 ml 0.8 N HClO, at -190"C. The other half was 
freeze dried to determine dry weight. The acid homage· 
nate was thawed and centrifuged at 4 °C. Two milliliters 
of the supernatant fluid were neutralized with about 200 
~-tl 6 N KOH. After centrifugation. 20 I-Ll of the superna-
tant fluid were used for the determination of nucleotides 
and creatine phosphate with HPLC according to Harm-
sen et al. (8). 
To determine 1"'C radioactivity in the ATP and GTP 
fractions, a fast, isocratic HPLC separation was devel-
oped. A Partisil-10-SAX column (\Vhatman, Ylaidstone, 
UK) was eluted at .3.0 ml/min with 0.42 M KH2 P04 , pH 
4.20. One milliliter of neutralized heart extract was in-
jected. Fractions were collected and counted (Fig. 2). In 
addition 50 ~-tl of this extract were counted to determine 
total 1'C-radioactivity uptake in the heart. Values were 
corrected for blanks. 1"1C-counting efficiency was S.'i-90%. 
Coronary flow measurements. :\llean coronary flow was 
measured by timed collection of perfusate in the periods 
described above. 
Statistical analysis. For statistical evaluation, analysis 
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FIG. 2. hocrmic HPLC ~epamtion of ATP and GTP. On~ milliliter 
ot· neutralized heart extract was injected on a Partisil-SAX column and 
eluted with a flow of :J.O ml/min with 0.42 m:Yl KH,PO,. pH 4.20. 
of variance was used (2-way classification); further com-
parisons were made using Scheff€'s method for multiple 
comparisons (19). When only two means were compared, 
Student's unpaired t test was used. P > 0.0.5 was consid-
ered not significant (l\'S). Results are given as means± 
SE. Three treatments (hypoxanthine, inosine, or hypo-
xanthine + ribose) were tested during two conditions 
(normoxia or reperfusion). Analysis of variance revealed 
that one experiment (hypoxanthine+ ribose during nor-
moxia), in which the ATP and GTP biosynthesis rates 
were 4.4;3 and 0.83 nmol-min- 1 -g dry wt- 1, respectively. 
contributed the major part of variance. The means± SD 
for all experiments in"" 26) were 1.06 ± 0.71 and 0.31 ± 
0.11 nmol-min-1 -g dry we'. respectively. According to 
the rejection rule of Anscombe and Tukey (see Ref. 19) 
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with a premium of 5:'/i.·, the values of the experiment 
mentioned earlier were considered as gross errors and 
rejected. The recalculated biosynthesis rates for ATP 
and GTP for all experiments were 0.92 ± 0.19 and 0.29 
± 0.06 nmol- min-1 • g dry wt- 1, respectively (n = 25). 
HESULTS 
In Fig. 3 mean coronary flowg during the various 
periods are presented. During period 2, flow was re-
stricted to 1::1 ml-min-1 -g dry wt- 1 (f1ow reduction of 
80%, P < 0.001 vs. control). In the firstS min of reper-
fusion the average flow increased to above control level 
(level 8, reactive hyperemia; P < 0.001 vs. control), but 
in period 4 t1ows in control and postischemic hearts were 
comparable. In preliminary experiments we investigated 
the time dependency ofh_ypoxanthine and inosine release 
during and after myocardial ischemia (Fig. 4-). After 
induction of ischemia, inosine and hypoxanb.ine ap-
peared in the coronary effluent. However, within the first 
5 min of reperfusion (reactive hyperemia, period 3) ino-
~ine and hypoxanthine returned to control levels (<0.1 
pM). 
Total normoxic purine release (i.e .. adenosine, inosine, 
hypoxanthine. xanthine, and uric acid) was about 20 
nmol- min-'· g dry wt- 1 (Fig .. 5: period 2, control}. This 
purine release was increased about six times during is-
chemia (P < 0.001 vs. control) and nine times during 
reactive hyperemia iP < 0.001 vs. control). During nor-
moxie perfusion 6-1% of the purines released consisted of 
uric acid, but during ischemia this percentage fell to 28%. 
The percentages of the other purine compounds in the 
perfusate collected during normoxia were (with :schemic 
values in parentheses) adenosine 5 (11), inosine 17 (38), 
hypoxanthine 8 (13). and xanthine ,5 (9), respectively, 
B CONTROL ISCHEMIA/ REPERFUSION 
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FIG. 8. Coronary flow ofnormoxic and iochemic hearts. retrogradely 
perfu~ed with a modified Tyrode solution, gassed with 95% 0,-5% CO,. 
at a perfusion pre>sure of i'2 mmHg and a heart rate of ~00 hats/min. 
Ischemia was introduced with a roller pump at a fixed flow 0f 2.5 ml/ 
min. Period /. aerobic perfm;ion 10-20 min); period 2. ischemic period 
(20-40 min): perwd 3. reactive hyperemia (40-4.5 min): and period 4. 
reperfusion ;4.'i-60 minl.ln control he3rts no now reduction was used. 
ValueF are means± SE (rt = 4-6) . .o., P< 0.001 vs. control (t statistics). 
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FIG. 4. Myocardia! release or hypoxanthine (G---O! and ino~ine 1--1- Both compounds were determined in ~ft1uent with HPLC (see 
METHODS . Period.\ 1-~ are defined in ]ej!end to Fig A~erage of at least :J experiments. 
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FIG. 5. Total purine relea$e (adenosine+ inosine+ hypoxanthine 
+ xanthi.1e + uric acid) from isolated rat heart,;. Period.,- 1-:J are 
defined in legend of Fig-. :1. Values are means :t SE In = 4-6\. A. P < 
0.001 vs. control (I statistics) 
In Table l. the biosynthesis of ATP and GTP from 
0.02 mM hypoxanthine or inosine is presented. Analysis 
of variance for hypoxanthine and inosine incorporation 
rates ir. the ATP fraction showed no significant inter-
action IP ""' 0.65) between the conditions normoxia and 
reperfusion on the one hand and the three treatments 
(infusicn of hypoxanthine, of hypoxanthine + ribose, 
and of :nosine) on the other hand. Thus the pattern fJr 
the three treatments was similar for normoxia compared 
with reperfusion. Incorporation r&tes during reperfusion 
TABLE L Uptake and incorporation rates of 
hypoxanthine and ino.o;ine 
===oo~~~~ 
Totdl Lptake ATP GTP 
Nurmuxia 
Hypuxamhme 84 ± 12 6.4 ± 0.9 2.0 ~ 0.4 
H_,pctxamhine 9:1 ± 21 16.0 ± l.:l 5.:1 ± 0.4 
+ribose 
lnusin~ 101 ~ 8 (100%1 7.:1 ± ).:) (7'(;.) 2.8 ± 0.4 (3%1 
Hypoxanthme 
Hypoxanthine 
+ribose 
lnosme 
Reperfusion 
9fi ± 7 14.6 ± 0.5 115~01 :3.9 ± ().~ 
91 ± 14 22.:3 ± 1.:1 126S·i) 7.2:0.7 
12:l = 14 \100%) 16.3 ± 2.ii (l4'Xd 4.9 ± 0.6 14%1 
Values ar~ menno::: SE in nmol-15 min '·f' dry wt' (n 3 6). 
Ft~ure< in parentheses are percent~ of total '·'C-radiolabel uptake by 
tis;ue. [8-'"'C]hypoxanthine or [8-"Cjinosine conven<ion to ATP and 
VfP and uptake of radioactivity were decermined in acid extractR of 
freeze-damped hearts. For otatigtic~l analy~i~, ~ee text 
were signi!icantly (P < 0.0001) increased compared with 
the normoxic controls. Comparison of the three treat-
ments proved them to be statistically different (P < 
0.0001). In addition, by Scheffe's method of multiple 
comparison the incorporation rates in the group treated 
with hypoxanthine + ribose were found to be different 
from the groups treated with hypoxanthine or inosine. 
the latter two not being different. Also the GTP incor-
poration rates showed no significant interaction (P = 
0.97) between normoxia/reperfusion &nd the three treat-
ments. The significant differences paralleled those ofthe 
ATP incorporation rates. 
Besides incorporation im.o nucleotides, the other met-
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TABLE 2. Metabolic fate of [BJ'C]hypuxanthine 
and [8-HC]inos·ine 
P~rcent nfLobellnlu<~d 
Aclditwn 
---
__ " ___ 
Nnrmoxia 
Hypoxamhine 0.9 f\'2_~ 
"-" 
r; 
±0.~ ±()_'i ±0.2 ±0.6 
Hypoxanthine 0.9 0.5 
"·' 
4-~ 
+ ribo~~ ±0. l ±0.2 ±U.S ±IH 
]no<itw l.4 RJ.1 ~-~ 7.:{ 
±0.1 ±~.9 ±0.:! ±O.l :!:IJ.l 
Reper[u.'i"n 
Il:>'J"'x,mthine O.S 0.2 :·\:l.l G.l 2Ji 
±0.1 ±1_1.1 :::0.~ ±0.:) 
H_vpoxdnthine 0.9 o.~ 7.0 
' ' + ribo<e ±0.1 :::0.?. ±J.l ±0.'2
Jnn~ine l.!i -~2.4 ~-~ 7.1 
:;t:IJ.l ±1.4 :'::IJ.~ ±IJ.~ ±0.1 
-----------------
V~lue.< lmeans ± SEJ ropre<ent radioactivitY recovned in \'anous 
hi,dqJre~oure liquid chromatography fraction;; of perfusJte_ L"ptake i~ 
cakubted from "C·radiolalwl me.osured in extracts 01' fret>:f·clamped 
lwurt<'. DBW are expre8sed as perrent of [5."C]hypoxanthine or [S-
"'C[inni'ine otlered to hearts (n = 4-li). F<Jr <tnliotical ·Jnalysis, 'ee 
text 
abolic fate of inosine and hypoxanthine was conver.-;ion 
to xanthine and uric acid. We determined [8-1-'C]inosine 
or hypoxanthine conversion in the coronary· effluent 
(Table ~). About 80S{, of both purines passed the heart 
unchang-ed and l0-15% were metabolized during a single 
passage through the coronary vasculature. About 0.8% 
of hypoxanthine was taken up by the heart, whether or 
not ribose was added. On the other hand. [8- 1-'C]inosine 
uptake was about 1.5%, which is twice the hypoxanthine 
uptake (P < 0.001). Incorporation rate:< were comparable 
for hypoxanthine and inosine. During reperfusion, the 
uptake figures for these purines were comparable to the 
control values. In the statistical analvsis of the uric acid 
data neither the interaction nor the- reperfusion versus 
normoxic data were statistically significant (P = 0.76: P 
= O.GO, respectively). The three treatments. however, 
were significantly different (P < 0.0001); by ScheffE~'s 
method of multiple comparison a significant difference 
(P < 0.001) existed between the group treated with 
inosine and the groups perfused with hypoxanthine in 
the presence or absence of ribose. Furthermore, perfusion 
with a mixture of ribose and hypoxanthine increased the 
uric acid release significantly (P < O.O·J) compared with 
hy-poxanthine infusion. 
Table :3 shows the data on energy·-rich phosphates 
determined in freeze-clamped hearts. During ischemia, 
total adenine nucleotides (TA.0JL ATP. and creatine 
phosphate (CrP) fell (20, :30, and 5()'?'(,_ respectively). 
Two-way analysis of variance showed a borderline ;;ig-
nificant interaction between normoxic and reperfused 
hearts with respect to TA='f (P = 0.13) and ATP (P = 
0.06), i.e., the decrease ofT AN and ATP due to ischemia 
and reperli.1sion disappeared when 0.02 mM inosine was 
added to the reperfusion buffer. CrP during reperfusion 
showed an overshoot in all groups studied (P < 0.001, 
interaction 0.11). 
H4l 
mSCCSS!Ol\' 
Theoretically nucleotide synthesis rates from radio la-
beled purines should be calculated on the basis of specific 
activity of the intracellular purine compounds. However, 
we were unable to measure intracellular hypoxanthine 
and inosine concentrations. To overcome this problem. 
we assumed that the hy-poxanthine and inosine concen-
trations in the heart cell were reflected bv the concentra-
tion~ in the coronary effluent. As is shOwn in Fig. 4, 5 
min after ischemia inosine and hypoxanthine concentra-
tions returned to normal values (<0.1 ,_,M). Therefore we 
crmcluded that within .5 min after ischemia, inosine and 
hvpoxanthine concentrations in the heart cell had also 
returned to control values, which are low in heart (<1 
i-'M. see, e.g., Ref. 20). To minimize isotopic dilution, 
0.02 ml\1 [R-"C]hypoxanthine or -inosine were used. 
Hypoxanthine and inosine incorporation rates were 
about 0.4 nmo!-min··l.g dry wC' into the ATP and 0.1 
into the GTP pool (8 anC: 2% of the "C radioactivity 
accumulated in the heart, respectively; see Table 1). In 
earlier experiments we showed that about 75% of [U-
1'Cjinosine (abo labeled in the ribose ring) recovered in 
nc.cleotides was incorporated into the cOmbined ATP 
and G TP pool both in normoxic and in reperfused hearts 
(7!. Therefore we estimated that the total hypoxanthine 
and inosine incorporation into adenine and guanine nu-
cleotides amounts t.o about 0.7 nmol-min-'-g dry wt- 1 
during aerobic perfusion. After ischemia a twofold in-
crease in the incorporation rates of these purines into 
A'LP and GTP is :>een. The total amount of raciioactivity 
w.ken up by the heart is not changed. however. Thus the 
percentage of hypoxanthine and inosine in heart, con-
TABLE :L Concentratio!I.I of hiMh-energy phosphates 
irt jrce2e-c/amped rat heorts 
Ad<iHHll1 AllP A:VtP (;TJ' CrJ' 
N<Jrnwxia 
None 2S.~ Jnl .j_,~ ().~ ().9 
±U ±il.:l ±0.2 ±0.1 
ll:>""JOX"nthine 22.1 4.,) o.:1 ].() :no 
±1.7 c:O.l ±O.:l ±2.G 
ll_vpoxanthitw 28.G (i.!i ().~ :l-3.1 
+ rihuse ±Ui ±t.:J ±(U ±0.1 ±0.1 :::::).8 
Inn,ine ~(i_:l 21.1 .k(i (}_~ 0.8 :!~_:) 
::::~.1 ±Ui ±IJ.Ii ±tl-~ ±tU ±J..'l 
f,,,·hemia 
~:UJ 1-'i.S .'i.S J.-1 0.1 l:U 
±2.1 ±~-8 ::::Ll ±tUi ±0-~ ±1.8 
!lepeifu>iun 
:\one ~u !i./1 :lA ().!i O.i 4~.9 
±Ll ±l.:! ±lU ±(U ±0.1 ±i.!i 
H_\'P<>xanthitw ~:l.7 19./i :1.<1 ()_:[ ()_<:\ 44.:1 
±LO ±LO ±0.1 ±ILl ±()_] ±:3.7 
Hypoxanthine 24.-'i ~..'i O.D 0.7 44.1 
+ rihn.<~ :t:l.IJ ±IJ.:l ::::(1.1 ±0.1 ±9.2 
]nosin~ ~G.~ 4.U (1.4 0 0 ·.r;s 
±U ±0.9 :t:0.2 ±0.1 ±0.1 ::::1.7 
\'nlues nre me.ms ± SE PJ = :)--()1 in !lmol/g- dry wL Hearts Wfre 
pNi'u,cd <'·" d~scribed in legend to Fig. :1. lsclwmia refer> w heart.< 
preperfu,;ed for~() min. with an addilional 20 minot- i'rhemia. For 
'tatistil'.li anal,v>i,. <ee text. TA:\, tnt,• I adenine nudeotide' 
H42 
verted to ATP and G TP. is increased. The rest of the 
14C label is found in the fraction containing the nucleo-
sides and oxypurines (see Ref. 8). \Ve have not measured 
myocardial nucleosides and oxypurines, but we assume 
that mor·E than SO% of the myocardial purine fraction 
consists of hypoxanthine {during hypoxanthine infusion) 
or inosine (during inosine infusion), as ref1ected by the 
perfusate concentration {see Table 2). If hypoxanthine 
and inosine were evenly distributed over the myocardial 
cells and extracellular space, intracellular hypoxanthine 
or inosin~ concentrations are estimated to be minimally 
15 liM. These concentrations are in the same order of 
magnitude as found in the perfusate. Therefore ATP and 
GTP biosynthesis is not limited by purine transport but 
is regulated intracellularly. According to Zimmer et aL 
(24), the ~ADP-to-NADPH ratio decreases during and 
after ischemia, and the hexose-monophosphate shunt is 
accelerated. As a result of this process, ribose-,'i-phos-
phate levels are increased, which in turn increases the 
PRPP concentration. Because hypoxanthine phospho-
r)dation is PRPP dependent, this could give a reasonable 
explanation for increased salvage rates after ischemia. H 
is possible to bypass the hexose-monophosphate shunt 
by supplying ribose as a precursor fOr PRPP (2:3). Indeed 
after ribose infusion, a significant increase in salvage 
rates is seen, which is further enhanced after ischemia. 
Namm (14) found that during normoxic perfusion 0.01 
mM inosine or hypoxanthine is incorporated into iso-
lated rat hearts at a rate of about :3 nmol-min- 1 -g dry 
we 1• Using myocardial homogenates of the same species. 
Maguire et aL (1.'3} measured hypoxanthine phosphori-
bosyltransferase (HPRT) activities with a maximal ini-
tial velocity (V,aJ of about 40 1-'mol-min-1 -g dry we'. 
This is o.bout 10,000 times higher than the salvage rates 
reported by Namm (14) or found in our experiments. 
Although an in vitro enzyme activity measurement can 
hardly be compared with in vivo activity, it seems that 
the hypoxanthine incorporation is not limited by the 
potentially available HPRT activity. Raivio et a!. (15) 
have found a striking correlation between PRPP synthe-
sis and cellular phosphate concentration in human fibro-
blasts. Myocardial PRPP synthesis could be regulated 
by phosphate concentration as well. 
During hypoxanthine perfu.,ion (with or without ri-
bose) after ischemia, a slight (J:\8) increase of TAN is 
seen. During postischemic inosine infUsion, however. 
TAN and ATP are about 5 (.lmol/g dry wt higher. AT!? 
biosynthesis from !8.1-'Cjinosine during reperfusion is 
1.1 nmol.min- 1 ·g- dry wt- 1 (Table 1). so TAl:\ synthesis 
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will be about 1.5. This is insufficient by far to account 
for the observed total restoration. There are two other 
known pathways that could account for ATP biosyn-
thesis. namely adenosine phosphorylation and de novo 
synthesis. Adenosine phosphorylation accounts maxi-
mally for 60 nmol-min- 1 ·g dry wt-' (14, 16). However, 
the adenosine concentration in the perfusate at the end 
of the ischemic period is about 1.2 1-'mol/1 and is lowered 
within ,5 min of reperfusion to 0.04 1-'mol/1. Therefore, 
under these experimental conditions, adenosine phos-
phorylation will be low because of lack of substrate. De 
novo synthesis in isolated rat hearts is 0.1 nmol·min- 1 • 
g dry \VC1 (23). This synthesis rate is PRPP dependent 
and is accelerated after ischemia. Whether de novo syn-
thesis is stimulated by inosine is unknown at this mo-
ment, but it seems unrealistic to assume that the resto-
ration of TA;-.J and ATP is due to de novo synthesis. 
Bates et al. (J) postulated the existence of a pool of 
nonacid-extractable ATP, which under certain condi-
tions can be converted to acid-extractable ATP. It re-
mains to be seen ;vhether this explanation is applicable 
to our results. 
During reperfusion an overshoot of creatine phosphate 
is seen (Table .'3). In the model of Saks et al. (l i) CrP 
serves as an "energy carrier" from mitochondria to sites 
of utilization. In this scheme it is possible for the mito-
chondria to start producing energy after mild ischemia, 
without direct utilization. For that reason, no CrP over-
shoot would be expected after severe ischemia, when the 
mitochondria are damaged (see Ref. 18). 
To our knowledge, this is the first report describing 
purine incorporation into the myocardial GTP pool. al-
though Swain et al. (20) recently reported restoration of 
GTP levels by de novo synthesis in dog heart. It is 
interesting to see that the purine incorporation rate into 
GTP is about 2.1% of that of ATP, although the GTP 
content in heart is only about,')% of the ATP content. 
This indicates a faster recovery of GTP after ischemia. 
Our final conclusions are that hypoxanthine and ino-
sine are incorporated in both the ATP and GTP pool in 
the heart. This process is stimulated after ischemia and 
by ribose perfusion and is thereby dependent on myocar-
dial PRPP concentrations. Inosine especially seems to 
restore ATP levels, and this could (partly) explain its 
beneficial action. 
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(l) The coronary vasodilator adenosine can be formed in the heart by breakdovnt of AMP or S~adenosyl~ 
homocysteine (SAdoHq). The purpose of this study was to get insight into the relath·e importance of these 
routes of adenosine formation in both the normoxic and the ischemic heart. (2) A novel HPLC method was 
used to determine myocardial adenosine and SAdoHcy. Accumulation of SAdoHcy was induced in isolated 
rat hearts by perfusion with L-homocysteine thiolactone or L-homocysteine. The release of adenosine, 
inosine, hypoxanthine, xanthine and uric acid was determined. Additional in vitro experiments were 
performed to determine the kinetic parameters of S-adenosylhomocysteine hydrolase. (3) During normoxia 
the thiolactone caused a concentration-dependent increase in SAdoHcy. At 2000 p.M of the thiolacttone an 
SAdoHcy accumulation of 0.49 nmoljmin per g wet weight was found during normoxia. L-Homocysteine 
(200 p.M) caused an increase of 0.37 and 4.17 nmol SAdoHcyjmin per g wet weight during normoxia and 
ischemia, respecth·ely. (4) The adenosine concentration in ischemic hearts was significantly lower when 
homocysteine was infused (6.2 vs. 11.5 nmol/ g; P < 0.05). Purine release was increased 4-fold during 
ischemia. (5) The Km for hydrolysis of SAdoHcy was about 12 p.M. At in vitro conditions favoring 
near-maximal SAdoHcy synthesis (72 p.M adenosine, 1.8 mM homocysteine), the synthesis rate in 
homogenates was 10 nmoljmin per g wet weight. (6) From the combined in vitro and perfusion studies, we 
conclude that S-adenosylhomocysteine hydrolase can contribute significantly to adenosine production in 
normoxic rat heart, but not during ischemia. 
Present addr~ss: Department of Medicine and Medical 
Physiology, Foothills Hospital. Cniversity of Calgary, 1203 
29th Street. N.W. Calgary, Alb~rta T2N2T9, Canada. 
Present address: Department of Biochemistry. University of 
Oxford. South Park Road, Oxford OXl 3QC. U.K. 
Abbreviations: SAdoHcy. S·adenosylhomocysteine: EHKA. 
ery thro"9-( 2-h y droxy-3-nonyl )ad~nine-H Cl: 1-Jepes. 4·(2· hy-
droxyethyl )-1-piperazineethanesu lfonic acid. 
Introduction 
Myocardial adenosine has been implied as 
metabolic regulator of coronary flow [1,2] and as 
attenuator of catecholaminergic effects during 
myocardial ischemia [3]. Chronotropic and dromo-
tropic influences of adenosine on the heart have 
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also been reported [4], as well as influences on 
adenylate cyclase [5], possibly via specific adeno~ 
sine receptors [6.7]. Formation of adenosine can 
occur either via hydrolysis of AMP [8] or via 
hydrolysis of S-adenosylhomocysteine ( SAdoHcy) 
by the enzyme S-adenosylhomocysteine hydrolase 
(EC 3.3.1.1). This last reaction is reversible \Vith 
equilibrium lying in the direction of SAdoHcy 
synthesis [9]. However. adenosine formed by the 
heart is quickly broken down into inosine and 
further into hypoxanthine, and in most species 
into xanthine and uric acid [10]. Adenosine can 
also be removed by phosphorylation to AMP [11]. 
Because the homoc:ysteine concentration. the sec-
ond reactant in the S-adenosylhomocysteine hy-
drolase reaction, is normally low and adenosine is 
removed quickly. any adenosylhomocysteine that 
is formed in the cellular methylation cycle [12] will 
be hydrolyzed to adenosine (Fig. 1 ). Schrader and 
co-workers [8.13] have investigated the properties 
of S-adenosylhomocysteine hydrolase from guinea 
pig heart. S-Adenosylhomocysteine hydrolase ac-
tivity in rat heart was found to be several-fold 
lower than in guinea pig heart [13]. 
We have perfused isolated rat hearts with L-ho-
mocysteine or homocysteine thiolactone in order 
to trap intramyocardially produced adenosine. 
both during normoxia and during low flow 
ischemia, when adenosine formation is increased. 
The results of perfusion studies are combined with 
those of in vitro studies in which we have 
determined the kinetic parameters of S-adenosyl-
homocysteine hydrolase. We suggest an important 
role for this enzyme in the regulation of the 
adenosine concentration in the normoxic, but not 
Fig. 1. Pa·_hways of myocardial purine metabolism. \1, methyl-
ation cycle; Hey. homocysteine: SAdoHcy. S-adenosylhomo-
cysteine: ADO. adenosine: 1:'--10. inosine; HX, hypoxnnlhine: 
X. xanthine; UA, uric acid 
in the ischemic heart. Preliminary results of this 
study have been published in abstract form [14]. 
Materials and Methods 
Chemicals 
All chemicals were analytical grade. Water (used 
for HPLC buffers and perfusion and assay media) 
was purified with the Milli-Ro4jMilli-Q system 
(Millipore Co .. Bedford. MA). L-Homocysteine was 
prepared by alkaline hydrolysis of L-homocysteine 
thiolactone according to Duerre and Miller [15] 
for perfusion studies. or according to Ueland [1 6] 
for in vitro studies. In the latter KOH was used 
instead of NaOH, with neutralization to pH 7.4 
instead of 7.0. L-Homocysteine thiolactone was 
obtained from Sigma (St. Louis, MO). EHNA was 
purchased from Burroughs Wellcome, Research 
Triangle Park. NC. 
Perfusion of rar hearts 
Hearts from male Wistar rats (275-350 gram). 
fed ad libitum. were excised and retrogradely per-
fused as described before [17]. Perfusion medium 
consisted of a modified Tyrode's solution, contain-
ing 125 mM N"aC\, 4.7 mM KCl, 1.35 m\1 CaC1 2 , 
20 mM KaHC03 • 0.4 mM NaH 2P04 , 1.0 mM 
MgC1 2 and 10 mM glucose. It was gassed with 
95% 0 2j5% C02 • Perfusion pressure was 72 
mmHg. The temperature, measured in the cannula 
tip, was maintained at 37.0 ± O.S"C. Ventricles 
were paced (4 V. 2 ms) at 300 beats/min. In the 
experiments where homocysteine was infused. 
coronary flow was kept between 9 and 10 mljmin 
by a rollerpump (LKB, Stockholm. Sweden, model 
2132) for an equilibration period of 15 min. Ho-
mocysteine was kept in perfusion medium gassed 
with 95% N 2j5% C02 in order to prevent oxida~ 
tion and it was infused into the perfusion system 
less than 5 s before it entered the heart. The final 
homocysteine concentration was 200 11M with 85% 
0 2/10% N 2j5% C02 . Ischemia was induced by 
reducing coronary flmv to 2.0-2.5 mljmin via the 
rollerpump. Perfusion with homocysteine \Vas con-
tinued for 20 min. Controls did not receive homo-
cysteine, but were otherwise treated identically 
(85% 0 2 • etc.). 
When homocysteine thiolactone (1 00-·2000 p.M) 
was infused in a preliminary series of experiments, 
equilibration time was also 15 min. but coronary 
flow was not regulated by a pump, and infusion of 
the thiolactone lasted 15 min. 
Assay of purine compounds 
Adenosine, inosine. hypoxanthine, xanthine and 
uric acid that were released from the hearts into 
the perfusates were determined as described previ+ 
ously [18]. Myocardial adenosine and SAdoHcy 
were determined in neutralized perchloric acid ex-
tracts of hearts that were freeze-clamped at the 
end of the experiments. The extracts were pre-
pared as described for adenine nucleotide de-
termination [19]. Neutralized extracts (200 p.l) were 
injected onto a Partisil SAX column (Whatman, 
Maidstone. U.K.) and eluted with 19 mM KH 2 P04 
(pH 2.85; flow, 2 ml/min). Adenosine and 
SAdoHcy eluted between 1 and 2 min. They were 
collected in a 2-ml sample loop, injected again 
onto a jJ-Bondapak C 18 column (Waters Associ-
ates. Milford, MA) and eluted with a KH 2 P04 
buffer (70 mM. 3% methanol added, pH 4.5) at a 
flow of 3 mljmin. The optimal time between 
injection onto the first column and switching of 
the sample loop to the second column was de-
termined with the use of standards. Moreover, 
SAdoHcy standards have been treated as in the 
procedure used for extraction of rat hearts. Re-
coveries were greater than 95%. 
SAdoHcy was also determined in samples of in 
vitro assays by the HPLC system for purine analy-
sis in perfusates (see next paragraph). 
In virro studies on rat heart SAdoHcy 
Direction of SAdoHcy hydrolysis. S-adenosyl-
homocysteine hydrolase activity in direction of 
hydrolysis was studied in preparations of rat heart 
which were partially purified by ammonium sulfate 
precipitation [20]. Enzyme activity was measured 
spectrophotometrically via the enzyme-cascade 
method described by SchUtz and collaborators [8]. 
K m and Vmux were determined in two separate 
experiments. The SAdoHcy concentration was 
varied (1-21 p.M) and activity per mg protein was 
determined. Lineweaver-Burk plots were used to 
determine Km and Vmax values. Protein was de-
termined using the Bio-Rad (Munich, F.R.G) pro-
tein assay [21], with bovine serum albumin as 
standard. 
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Direction of SAdoHr.y synthesis. Rat hearts were 
homogenized in 10 val. (mljg wet wt.) of 
HepesjKOH (10 mM, pH 7.4; 2 mM MgC1 2 , 1 
mM dithiothreitol). Filtration over nylon gauze 
was followed by centrifugation and removal of low 
molecular weight compounds by gel-filtration over 
a PD-10 column (Pharmacia, Uppsala, Sweden). 
Assay mixtures ,contained L8 mM homocysteine, 
72 !J-M adenosine and 5 p.M EHNA (final volume, 
2.4 ml), the latter to prevent breakdown of adeno-
sine by adenosine deaminase. Various amounts of 
homogenate were incubated at 37°C in the homo-
genization buffer. Samples (1 ml) were taken at 
different time intervals and were added to 1 ml 
ice-cold perchloric acid (8%). Protein was removed 
by centrifugation. After neutralization with KOH 
and removal of KCl04 by centrifugation (0°C), 
samples were injected on the HPLC system [18} 
described for purine determination. 
Sratistics 
Statistical significance was evaluated by Stu-
dent's t-test for paired or unpaired observations 
and P values (two-tailed) were calculated. P ~ 
0.05 was considered not significant. Results are 
expressed as means ± S.E. The number of experi-
ments is represented by n. 
Results 
Perfusion of isolated rar hearts 
Effects of homocysteine thiolactone infusion. Ho-
mocysteine thiolactone was infused at concentra-
tions of 0, 100, 430 and 2000 j.tM. Fig. 2 shows the 
myocardial SAdoHcy and adenosine after 15 min 
of perfusion with the thiolactone. SAdoHcy in-
creased with increasing thiolactone concentrations, 
while myocardial adenosine concentrations in-
creased to control levels after an initial decrease at 
100 I-'M of the thiolactone (Fig. 2). Table I gives 
the data on purine release from these hearts over 
the 15 min period of perfusion with thiolactone. 
Homocysteine thiolactone (100 !J-M) caused a de-
crease in purine release (Table I), but this was far 
greater than the observed intramyocardial SAdo-
Hcy accumulation (Fig. 2). At 430 p.M homocy-
steine thiolactone the purine release appeared to 
be equal to control level. Purine release at 2000 
p.M thiolactone could not be determined because 
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Fig. 2. Effect of homocysteine thiolactone on intramyocardial 
accumulation of adenosine and SAdoHcy_ Isolated rat hearts 
were retrogradely perfused (pacing, 300 beats/min). After 15 
min equilibration, hearts were perfused with homocysteine 
thiolactone for 15 min and freeze-damped at the end of the 
experiments. Adenosine and SAdoHcy were determined in 
neutralized perchloric acid extracts of the hearts. 0. adenosine: 
A. SAdcHcy. Values are means ± S.E. of four or five hearts. 
of the appearance of unidentified peaks in our 
chromatograms. We suggest that metabolic dis-
turbances occur, when high concentrations of ho-
mocysteine thiolactone are infused (see Discus-
sion). 
Effects of homocysteine infusion. In Table II 
results are presented of rat heart perfusions with 
200 fJ-M homocysteine during normoxia and 
ischemia. Special care was given to prevent oxida-
tive degradation of homocysteine before it entered 
the heart. Ischemia induced a 4-fold increase in 
purine release in both homocysteine-treated and 
TABLE. I 
non-treated groups. Total purine release during 
normoxia. as well as during ischemia was not 
influenced by homocysteine infusion. In normoxic 
hearts SAdoHcy levels were low (0.2 nmol/g wet 
wt.) and they increased to 7.6 nmol/g wet wt., 
when homocysteine was present. During ischemia 
homocysteine increased intramyocardial SAdoHcy 
from 0.6 to 84 nmol/g wet wt. during the 20 min 
perfusion period. This reflects the greater availa-
bility of adenosine during ischemia. Sequestration 
of myocardial adenosine by homocysteine was also 
suggested by the fact that the ischemic adenosine 
concentration (11.5 nmoljg) was significantly 
lower in the presence of homocysteine (6.2 nmol/g; 
p < 0.05). 
In vitro studies 
A dialyzed supernatant after 35% ammonium 
sulfate precipitation had an activity in the direc-
tion of SAdoHcy hydrolysis of 0.19 nmol/min per 
rug protein ([SAdoHcy] = 20 J.LM). The dialyzed. 
resuspended pellet of a 60% ammonium sulfate 
precipitate gave an activity of 0.51 nmol/min per 
mg protein. The Km of SAdoHcy in direction of 
hydrol:ysis was found to be 12-13 !J.M with a Vma" 
value of 0.7-0.8 nmoljmin per mg protein. The 
latter is equivalent to 18-20 nmol/min per g wet 
wL 
Under conditions of maximal SAdoHcy synthe-
sis (i.e., 1.8 mM homocysteine, 72 fJ-M adenosine, 
5 p,M EHNA and 37°C). the reaction was linear 
for only 15 min. Inactivation of the enzyme might 
be the cause [22]. The reaction was linear with the 
amount of enzyme and two separate determina-
tions gave an SAdoHcy synthesis rate of 9.6-10.4 
nmol/min per g wet wt. 
EFFECT OF HOMOCYSTEiNE THIOLACTONE ON }JORMOXIC MYOCARDIAL PURINE RELEASE 
Hearts were perfused as described in the legend to Fig. 2. Perfusates were collected on ice over 15 min. and purines were determined 
with HPLC. n, number of experiments: HcyT. homocysteine thiolactone: Ado. adenosine: lno, inosine: Hx. hypoxanthine: X, 
xanthine: UA. uric acid. Values are expressed as nmolj15 min per g wet weight±S.E. 
HcyT Ado Joe H' X UA Total purines 
(/•M) 
0 1.8 ±0.8 5.8±0.8 2.8±0.8 3.6 ± 1.0 28 ±6 42±4 
100 0.9±0.2 3.7±0.9 2.3±0.5 3_6 ±0.5 10.9±1.0 a 21 ± 3" 
430 4 0.3 ±0.3 9 ±3 L3±0.9 4.7± 1.4 37 ±5 52±7 
a P < 0.05 vs. 0 JL\1 homocysteine thiolactone. 
Discussion 
!!omo(}'Steine thiolacrone uersus homocysreine infu-
S/011 
Because of the fact that L~homocysteine \Vill be 
oxidized when dissolved in oxygenated perfusion 
medium. we started our experiments with homo-
cysteine thiolactone. The thiolactone is converted 
intracellularly to homocysteine. At higher con-
centrations, however, the thiolactone appeared to 
be toxic to the hearts. The occurence of acidosis. 
caused by intracellular hydrolysis of high amounts 
of the thiolactone. might be a factor responsible 
for this [23]. The observed decrease of purine 
release upon infusion of 100 Jl:.'vf thiolactone (Ta-
ble I) cannot be explained by the increase in 
intramyocardial SAdoHcy. L-Homocysteine (200 
11M), which we used for further experiments, gave 
a similar. although nonsignificant reduction of 
purine release (Table II) during normoxia. A pos-
sible explanation for the effects observed at lower 
concentrations of both compounds is reduction of 
glutathione by homocysteine [24], which might 
lead to alterations in myocardial oxidation/reduc-
tion state and metabolism [25]. 
Significall! adenosine production from SAdoHcy 
during normoxia 
Observations from our perfusion studies with 
homocysteine can be compared to the kinetic 
parameters of SAdoHcy hydrolase obtained from 
in vitro studies that are reported here and by other 
authors. We assume simple Michaelis-Menten 
kinetics to be applicable. 
The SAdoHcy concentrations in nm·moxic rat 
heart was found lo be 0.2-0.6 nmol per g wet wL 
This gives an estimated SAdoHcy concentration 
of 0.4-1.5 pJvL The Km for SAdoHcy hydrolysis 
was 12-13 11M with a Vrnax of 18-20 nmoljmin 
per g wet wt. The synthesis of adenosine from 
SAdoHcy in the absence of homocysteine can then 
be calculated to vary between 0.5 and 2.2 
nmoljmin per g wet wt. From measurements of 
rat heart methylation cycle [12] a value of 0.7 
nmoljmin per g wet wL was calculated, \Vhich is 
in good agreement with our estimate. Adenosine 
production during normoxia in the presence of 
homocysteine (200 11M) can be estimated from 
SAdoHcy accumulation to be at least 0.38 
397 
nmoljmin per g wet wt., but more than 10-fold 
higher (4.2 nmoljmin per g) during ischemia. 
:-Jormoxic purine release amounted to 7 ± 4 
nmoljmin per g wet wt. and was increased 3-fold 
during ischemia (20 nmoljmin per g; Table II). 
Considering the kinetic parameters of the enzyme 
in the direction of synthesis [14] and of adenosine 
deaminase. one would not expect a more than 
10-fold rise in SAdoHcy accumulation. due to 
homocysteine infusion during ischemia with a 
simultaneous 4-fold rise in total purine release. 
The Km (adenosine) of S-adenosylhomocysteinase 
is lower than 1 f.!M [15], while the Krn (adenosine) 
for adenosine deaminase is about 50 pM. This 
observed difference can be .::xplained by assuming 
extremely low normoxic adenosine concentrations 
in the cellular compartment (cytosol) that contains 
adenosine deaminase and S-adenosylhomocysteine 
hydrolase, for instance caused by the reported 
binding of adenosine to S-adenosylhomocysteine 
hydrolase [26]. In that case it has to be assumed 
that normoxic formation of purines takes place for 
a maJor part via AMP ...... IMP --. inosine and 
therefore bypasses adenosine formation. Other 
studies in our laboratory have recently supported 
this hypothesis: we have reported experiments [27] 
in which we infused a strong inhibitor of adeno-
sine deaminase into isolated rat hearts at a con-
centration which inhibited the deamination of in-
fused adenosine for more than 90%. The inhibitor 
(EHNA 50 11M) increased the relative release of 
adenosine during normoxia from 7 to 18% ( P < 
0.05) without changing total purine release. Dur-
ing ischemia EHNA increased adenosine release 
3-4-fold, i.e., to 60% of total purine release. These 
results suggest that purine formation by way of 
AMP--. IMP--> inosine could be of significance 
during ischemia. but could be especially important 
during normoxia [27]. The same has also been 
suggested for guinea pig heart [28]. Furthermore. 
the AMP concentration in normoxic myocardial 
cytosol is extremely low (1 !J.M) [29,30] and thereby 
limits adenosine formation from AMP simply by 
lack of substrate. From evidence that virtually no 
rephosphorylation of adenosine by adenosine 
kinase could be detected in normoxic rat heart 
[31], it can be concluded that normoxic free 
adenosine concentration is extremely low. More-
over. all evidence which suggests that AMP--> 
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adenosine is a major catabolic pathwa:y in the 
heart, is solely referring to conditions where the 
AMP concentration has been elevated (e.g., 
ischemia, hypoxia, increased work load. acetate 
infusion). The arguments mentioned here tend to 
decrease the importance of AMP as a source of 
adenosine formation during normoxia and thereby 
emphasize the relative importance of SAdoHcy as 
a source of normoxic myocardial adenosine pro-
duction. 
Minor adenosine production from SAdoHLy during 
ischemia 
Km values for homocysteine (direction of 
SAdoHcy synthesis) have been reported to be 
80-" 160 11M [32,33] and 260 p.M [13]. From our 
perfusion experiments, we calculated the SAdoHcy 
synthesis rate in ischemic hearts to be 4.2 
nmoljmin per g wet wt. In our in vitro assays (at 
saturating adenosine and homocysteine concentra-
tions) we determined a Vmax value of 10 nmoljmin 
per g wet wt. These values are in good agreement 
if we assume ischemic myocardial adenosine con-
centrations to be well above Km, and the homocy-
steine concentration (200 f.LM) in the range of K m· 
The fact that ischemic purine release was not 
significantly altered in the presence of homocys-
teine demonstrates a minor contribution of 
SAdoHcy hydrolysis to purine formation in the 
isolated ischemic rat heart No significant decrease 
of adenosine release could be detected in our 
experiments with ischemic hearts that were per-
fused with homocysteine. Schrader et al. [13] found 
a significant decrease of adenosine release from 
hypoxic (30% 0 2 ) guinea pig hearts perfused with 
homocysteine thiolactone. This difference can be 
explained by the fact that S-adenosylhomocys-
teine hydrolase activity in guinea pig heart is 6-fold 
higher than that in rat heart [13]. 
Concluding remarks 
The fact that homocysteine infusion during 
ischemia gave a significant decrease of intramyo-
cardial adenosine concentration without altering 
total purine release also supports the hypothesis 
that purine formation could occur in part via IMP 
during ischemia. In conclusion: if we assume (Refs. 
27, 28 and this study) that during normox.ia a 
considerable part of myocardial purines is formed 
399 
via AMP......,. IMP......,. inosine (see Fig. 1) and that a 
significant amount of intracellular adenosine is 
bound [26,34] to the enzyme (S-adenosylhomocys-
teine hydrolase), we can conclude that rat heart 
S-adenosylhomocysteine hydrolase could play an 
important role in the regulation of normoxic in-
tracellular adenosine formation and concentration. 
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Adenosine deaminase inhibition and myocardial 
purine release during normoxia and ischaemia 
PETE:R W ACHTERBERG,* EEF HARMSEN, AND JAN WILLEM DE JONG 
From the Cardiochemical Laboratory, Thoraxcenter, Erasmus University Rotterdam, P .0. Box 1738. 3000DR 
Rotterdam, The Netherlands 
SCMMARY Quantitative determination of myocardial adenosine formation and breakdown is 
necessary to gain insight into the mechanism and regulation of its physiological actions. Deamination 
of adenosine was studied in isolated perfused rat hearts by infusion of adenosine ( 1 to 20 
,u..mol·litre-1). All catabolites in the perfusates (inosine, hypoxanthine, xanthine and uric acid) were 
measured, as well as unchanged adenosine. Apparent uptake of adenosine was determined; it 
increased linearly with the concentration of adenosine infused. Adenosine was predominantly 
deaminated, even at low (l ,u..mol·litre-1) concentration. The inhibitory capacity of the adenosine 
deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was determined, while 5 
,u..mol·litre-1 adenosine was infused. EHNA inhibited the apparent adenosine deaminase activity for 
62 and 92% at 5 and 50 ,u..mol·litre-1 , respectively. When 50 ,u..moHitre- 1 EHNA was infused into 
normoxic hearts, release of adenosine was significantly elevated, as was coronary flow. Induction of 
ischaemia increased total purine release four- to fivefold. Infusion of EHNA into ischaemic hearts did 
not alter total purine release. but adenosine release increased from 15 to 60% of total purines. 
However, when EHNA was present, a large part of total purine release still existed of inosine, 
hypoxanthine, xanthiner and uric acid. This was 83% during normoxia and 40% during ischaemia. 
These results suggest significant contribution of IMP and GMP breakdown to purine release from 
isolated perfused rat hearts. 
Several aspects of adenosine metabolism are 
important to myocardial (patho)physiology. 
Regulation of coronary flow by adenosine 1 2 is 
probably the most important aspect. Furthermore, 
adenosine has been implied as attenuator of 
catecholaminergic effects in ischaemic heart. 5 
Chronotropic and dromotropic influences of 
adenosine in heart have also been reported. 6 Salvage 
of adenosine3 4 could be significant to preserve the 
myocardial ATP pool. Myocardial purine 
metabolism, however, is very complex. For example, 
several pathways can contribute to formation and 
breakdown of adenosine in the heart. 7 Adenosine can 
be formed via dephosphorylation of AMP by action of 
5'-nucleotidase (EC 3.1.3.5) or alkaline and acid 
phosphatase (EC 3. 1.3 .I), respectively or from 
S-adenosylhomocysteine (SAH) by means of 
SAH-hydrolase (EC 3.3.1.1.). Dephosphorylation is 
probably the most important. especially durir.g 
*To whom correspondence and reprint requests should be sent 
Key words· adenosine; adenosine deaminase; purine 
metabolism. 
ischaemia, when myocardial AMP levels rise 
strongly. 8 Removal of adenosine can occur by 
rephosphorylation to AMP (by adenosine kinase, EC 
2. 7 .l .20) or by deamination to inosine (by adenosine 
deaminase, EC 3.5.4.4.). Inosine can be broken down 
further to hypoxanthine. xanthine and uric acid (see 
fig 1). 
Quantitative determination of adenosine formation 
and breakdown in the heart is important to gain insight 
into the mechanism and regulation of its physiological 
actions, It has been tacitly assumed that the release of 
adenosine, inosine and hypoxanthine from the heart is 
a good measure of myocardial adenosine 
production. 9- 11 For several reas~ms this assumption 
could be wrong. It neglects adenosine kinase activity 
and it does not account for release of xanthine and uric 
acid, which can be relatively large, depending on the 
myocardial xanthine oxidase/dehydrogenase (EC 
1.2.3.2/1.2.1.37) activity of the species used. 12 
Furthermore, breakdown of adenine nucleotides in the 
heart might not only proceed by way of 
AMP____,.adenosine----?inosine, but also by way of 
AMP____,.JMP----?inosine or QMp____,.____,.xanthine. In these 
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• 
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HYPOXANTHINE SAH 
' !• L ____ .... XANTHINE-~URIC ACID. 
FIG 1 Pathways of purine metabolism 
Enzymes involved: I = 5' -nucleoridase: 2"" adenosine 
kinase: 3 = adenosinedeaminase:4 = AMP-deaminase: 
5 ""nucleoside phosphorylase: 6 = xanrhine 
oxidase!dehydro[;enase: 7 = SAH-hydro/ase. SAH = 
S-adenosylhomocysteine. Dmred fines: quanritarive/y minor 
pathways or parhways nor vet determined in rhe hean. 
*Purines which con be released from the hearr. 
last two cases adenosine formation is bypassed and 
total purine release would not be a good measure of 
adenosine formation (fig 1). 
One of the topics in myocardial adenosine 
metabolism over which some controversy exists, 
regards the rates at which infused adenosine is 
deaminated or incorporated into the heart. Jacob and 
Berne 13 have stressed the importance of 
phosphorylation, while De Jong 14 concluded that 
deamination was the most important fate of infused 
adenosine. 
We report rates of deamination and uptake of 
adenosine infused into isolated rat hearts and the 
inhibitory capacity of the adenosine deaminase 
inhibitor EHNA. Finally, endogenous fonnation and 
breakdown of adenosine in normoxic and ischaemic 
rat heart was studied by infusion ofEHNA. Our results 
suggest that not all purines released are produced via 
dephosphorylation of AMP to adenosine. 
Materials and methods 
CHEMICALS 
All chemicals were analytical grade. Water (used for 
HPLC buffers and perfusion media) was purified with 
the Milli-Ro4/Milli-Q system (Ylillipore Co. Bedford. 
MA). EHNA (erythro-9-)2-hydroxy-3-nonyl) 
adenine.HCl) was obtained from Burroughs 
Wellcome. Research Triangle Park, NC. 
PERFUSION OF HEARTS 
Male Wistar rats (275 to 350 g). fed ad fibirum. were 
used. After anaesthesia of the rats with pentobarbital 
(i.p.), hearts were quickly excised and immediately 
Peter W Achrerberg, Eef Harmsen. and Jan Wil/em de Jonr; 
arrested in ice-cold saline or perfusion buffer. a 
modified Tyrode solution. containing 10 mmol·litre- 1 
glucose. 15 The Langendorffpreparation was used with 
100 cmH20 perfusion pressure. Hearts were paced at 
300 beats·min- 1 (4 V stimulation for 2 ms). Perfusion 
temperature was kept at 37.0 ± 0.5°C. The medium 
was not recirculated and was gassed with 95%02 , 5% 
C02- Ischaemia was induced by reducing perfusion 
pressure to 20 to 25 cmH20. At the end of the 
perfusion hearts were either taken from the apparatus 
and blotted dry for wet weight determination, or freeze 
clamped. In the case of freeze clamping, dry weight 
was deterwined by freeze drying. For comparison: 
under our conditions l g dry weight equals about 7 g 
wet wt. 
CORONARY FLOW 
Mean coronary flow was determined by collection of 
perfusate in a graduated cylinder over five-minute 
periods. 
MYOCARDIAL FUNCTIOI" 
Apex displacement was used as an indicator of 
myocardial performance and measured as described 
previously. 16 It has been shown to correlate well with 
changes in myocardial pressure development during 
ischaemia and anoxia. 16 The displacement observed 5 
min after the start of the perfusion was taken as l 00%. 
ASSAY OF PURINES 
Adenosine. inosine. hypoxanthine, xanthine and uric 
acid were determined by a slightly modified version of 
the method described by Hannsen. 17 Briefly: 200 or 
250 ,u.l of perfusate were injected into a ,u.Bondapak 
C 18 column (30 X 0.4 em. Waters Assoc, Milford, 
MA) and eluted isocratically with 70 mm·litre- 1 
KH2P04 • pH 4.5, to which methanol was added. Flow 
rate was either I ml·min- 1 (10% methanol added to 
buffer) or 3 ml·min- 1 3% methanol added). Peaks 
detected at 254 nm were compared with those of 
standards. Some ischaemic perfusates were incubated 
with uricase (EC 1.7.3.3) and deproteinised with 
perchloric acid. After neutralisation, the 
disappearance of the uric acid peak was established by 
HPLC. 
DETERMlNATIO:-\ OF HIGH-ENERGY PHOSPHATES 
ATP. ADP, and Creatine Phosphate were determined 
in neutralised. perchloric acid extracts of 
freeze-clamped hearts by the method of Harmsen 18 
STATISTICAL ANALYSIS 
Statistical significance was evaluated by Student's r 
test for paired or unpaired observations and p values 
(two-tailed) were calculated. p>0.05 was considered 
to be not significant. Results have been expressed as 
Adenosine deaminase and myocardial purine release 
means ± SEM. The number of experiments is 
represented by n. 
Results 
METABOLIC FATE OF INFUSED ADENOSINE 
Infusion of increasing concentrations of adenosine (I 
to 20 ,u.mol·litre- 1) caused the release of increasing 
amounts of the catabolites inosine, hypoxanthine. 
xanthine and uric acid (fig 2). Inosine formation 
increased strongly with rising adenosine 
concentrations, while output of hypoxanthine, 
xanthine and uric acid rose more slowly. However, at a 
low adenosine concentration, the major pathway is 
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still catabolism and the majority of catabolites(>60%) 
consists of xanthine and uric acid. 
The sum of released catabolites reflects adenosine 
deaminase activity. This is shown in table 1, together 
with the (computed) apparent adenosine uprake. At all 
concentrations of adenosine studied deamination was 
found to be greater than uptake. Apparent uptake 
increased linearly with the amount of adenosine 
infused. 
EFFECTS OF EHNA ON CATABOLISM OF 
INFUSED ADENOSINE 
Table 2 shows the inhibition of apparent adenosine 
deaminase (ADA) activities by EHNA. Apparent 
0 FlG 2 Formation of purines from adenosine infused into 
~ ~--~-
"l/ .... ~~·····+ 0~ 
10 20 
J-IM Adenosine 
25 
1 so!ared rat hea/"ls were perfused with adenosine (rwo 
differenr concentrations per heart). Adenosine perfusions 
were preceded and followed by perfusion with medium 
alone. Each period of perfusion !asred ten minutes. Purines 
were determined inperfusates. collected durin!? the second 
5 min of each period. Values were corrected for average 
amounrs of purines. released in rhe absence of adenosine. 
Points are means of3 experiments± SEM.Ifnobarsare 
RiVen, SEM' sfa/1 within the size of symbols .!no= inosine 
(0!:Hx = hypoxamhine(\l ))X=xanthine( Ia): UA =uric 
acid(ll). 
TABLE I Deaminarion and apparent uptake of adenosine infused into isolmed rat hearts 
Adenosine UnchanRed Cazabolires* Apparem Coronary 
mpw adenosine released up rake flo.,· 
}Lmo!·lim:- 1 (nmo/·min- 1) mnol·min-1 per li wer WI (ml·min- 1 ) 
per g wet wl (% oj"inpw) per g wei wl 
16=3 3.3±0.4 (2JC,f) 10±2 163%} 2.7±0.9 (17'7c} 14±2} 
32±8 9±2 (28'7<} 19±3 !59~k) 3.5±0.5 (llo/c) 16±2 
10 179±5 110±3 {62'7cJ 52±2 129o/c) 17±4 (lOck} 17.4±0.3 
20 400:':: 10 286±48 (72'1::) 79::::3 (20'7c) 31±12(8"/c.) 19±2 
Isolated rat heart\ were perfused as described in the legend 10 l"1g 2 Apparent uptake wa~ computed from the difl"erence in adenosine input and 
oulput of tolal purine> 1 ie. unchanged adeno>ine plus catabolites}. ~calabolites "" sum of inosine. hypoxanlhine. xanthine and uric acid: this 
reflects adenosine deaminalion Mean<; ± SEM of 3 experiments 
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TABLE 2 Apparent adenosine deaminase acrivities and inhibition by EHNA 
Expr EHNA Adenosine infused Apparenr ADA aeli\'irv ADA inhibition 
(JJ.mol·lirrr 1 ) (o/o) 
(nmol·min- 1 per g wet wefghr) 
107±7 42±3 0 
112.1±1.3 16.2± 1.5~ 62 
11 105±7 49±3 0 
50 109+6 4.1 +0.2* 92 
After equilibration, adenosine (5 Mmol·litre-') was infused into isolated rat hearts. After another equilibration period, adenosine wa'i infused 
together with EHNA (Expt I: 5 ,.,_mol·litre-' and Expt II: 50 J.l.mol·litre-'). Equilibration and infusion of adenosine and EHl"A took place for 10 
min periods. Purines were determined in perfusates, collected during the second 5 min of each period. Adenosine input was determined from 
the infused adenosine concentration. Apparent adenosine deaminase (ADA) activities were computed by summation of inosine, 
hypoxamhine, xanthine and uric acid release. Values were corrected for the average purine relea~e before and after adenm;ine infusion 
X± SEM (n = 4): *p<O.OOJ vs 0 ,.moHitre- 1 EHNA. 
ADA activities were computed by summation of 
release of inosine, hypoxanthine, xanthine and uric 
acid, corrected for control release of purines. EHNA 
(50 ,umol·litre- 1) inhibited the deamination of 5 
,u.mol· J.itre- 1 adenosine by more than 90%. 
EFFECTS OF EHNA DURING NORMOXJA A!'-:D 
lSCl-lAEM!A 
Fig 3 shows the results of measurements of coronary 
flow and myocardial function (apex displacement) in 
hearts perfused with or without 50 ,u.mol·litre~ 1 
EHNA. When EHNA was infused during normoxia, 
apex displacement was not significantly changed. 
Normoxic coronary flow increased more than 50% 
(p<0.05) in the presence of EHNA. Reduction of 
perfusion pressure from 100 to 20 cmH2 0 decreased 
coronary flow and reduced apex displacement in the 
absence as well as in the presence of EHNA. 
Purine release from these hearts is shown in fig 4. 
During normoxia. EHNA induced a small but 
signif1cant (p<0.02) rise in adenosine release, 
although the relative release of inosine. hypoxanthine, 
xanthine and uric acid remained high (80%). Total 
normoxic purine release was not altered. When hearts 
were made ischaemic, adenosine release was 
increased three~ to fourfold by addition of EHNA 
(p<0.02). Release of inosine. hypoxanthine and 
xanthine was lower in the presence of EHNA 
(p<0.02). Uric acid release was also lower. but the 
difference was not statistically significant. Total 
ischaemic purine release was not altered by EHt\A. 
These results indicate inhibition of myocardial 
adenosine deaminase activity during normoxia and 
ischaemia. Still a considerable amount of inosine, 
hypoxanthine, xanthine, but especially uric acid was 
released. 
MYOCARDIAL HIGH-Et"ERGY PHOSPHATES 
After 15 min of mild ischaemia (experiments of fig 4) 
the following levels of high-energy phosphates were 
found in the absence of EHNA: ATP, 20.4 ± 1.5; 
ADP, 5.3 ± 0.9; Creatine Phosphate, 24.9 ± 1.3 
(,u.mol per g dry wt.; X± SEM; n = 4). Addition of 50 
pmol·!itre~ 1 EHNA during ischaemia caused no 
significant differences: ATP, 23.8 ± 0.9; ADP 6.2 ± 
0.4. and Creatine Phosphate, 25.7 ± 1.3 (.u.mol per g 
dry wt.). 
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After 15 min of equilibration, isolated rat hearts were 
perfused in the absence rO and \1) or presence (8and A) of 
50 p..mol·litrC1 EHNA. At t = 25 min hearts were made 
ischaemic b.v reduction of perfusion pressure. AD = apex 
displacement( AI. and \1 ). CF = coronaryjlow(Oand8). 
AD at t = 5 min was taken as 100%. Data are meansof4 
experiments± SEM.lf no bars are given, SEM' sfa/1 within 
size of the symbols. 
*p<0.05 vs non" treated. 
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FIG 4 EffectofEHNAonreleaseofpurine 
nucleosides and oxypurines from norrnoxic 
and ischaemic rat hearts. 
Isolated rat hearts were perfused in the 
absence (A) or presence (8) of 50 f.U11Dl·litrC 1 
EHNA as indicated in the legend to 
!5 20 25 30 35 40 !5 20 25 30 35 
fig 3. Purines were determined in perfu.sates 
collected over 5 min periods. Purine 
nucleosides:Ado = adenosine(8); /no= 
inosine (0). Oxypurines:Hx =hypoxanthine 
(V );X= xanthine ( 6); UA =uric acid (Ill). 
Values are means± SEM (n = 4). Significant 
differences (andp values) between the groups 
offigs4a and 4b are given in the results 
secrion. minutes minutes 
Discussion 
In quantitative studies on myocardial purine 
metabolism, one has to make certain that all 
compounds contributing to purine efflux have been 
measured. In many studies, however, xanthine and/or 
uric acid have not been determined. Still, myocardial 
xanthine oxidase/dehydrogenase activity has been 
reported in man, cow, sheep, dog, cat and rat. For 
example, in the isolated perfused rat heart xanthine 
and uric acid make up 70% of purines released during 
normoxia. 12 Moreover, our experiments show that 
infusion of low amounts of adenosine (I ,umol·litre-1) 
gives rise to 60 to 70% of catabolites recovered as 
xanthine and uric acid. Breakdown of exogenous 
adenosine up to uric acid in rat heart has been reported 
with 5 ,umoHitre-1. 19 Our results are in good 
agreement with that study. At all concentrations of 
adenosine studied, deamination was found to be 
greater than uptake, which increased linearly with the 
concentration of infused adenosine. If catabolites are 
also accumulated by the heart, phosphorylation 
(apparent uptake) would be even lower and 
deamination higher than we show in table 1 . However, 
the rates of apparent adenosine uptake that we 
computed agree very well with the rates of 
14C-adenosine incorporation into the adenine 
nucleotide ~ool of isolated perfused rat hearts reported 
by Namm.- 1 
Simultaneous infusion of adenosine and EHNA did 
not inhibit apparent adenosine uptake and EHNA did 
not change the total purine release from normoxic or 
ischaemic heans. Therefore, we conclude that EHNA 
did not interfere with myocardial purine transport in 
our experiments. Furthermore, EHNA did not disturb 
normoxic or ischaemic myocardial function or energy 
metabolism as can be concluded from our 
measurements of apex displacement, purine release 
and myocardial high energy fthosphates. Our studies 
confirm the observation3 0 that there is no 
ATP-sparing effect of ENA and no increased salvage 
of adenosine during ischaemia in the presence of 
EHNA. We found no indications of an inhibitory 
effect of EHNA on myocardial AMP-deaminase as 
was suggested elsewhere26 for cultured cells, but was 
not found in in vitro assays of AMP-deaminase from 
rat polymorphonuclear leucocytes. 27 
Our results are compatible with several hypotheses. 
Firstly, one could assume that EHNA does not reach 
the myocardial compartment where adenosine is 
formed and deaminated, but that EHNA inhibits 
adenosine deaminase in a compartment to which 
adenosine is transported after formation ( eg 
interstitium, endothelium). The· fact that EH:"J"A is 
active in experiments with isolated cultured cells 9 does 
not support this hypothesis. A second hypothesis is 
purine formation from IMP and GMP. Myocardial 
purine formation by way of AMP-IMP-inosine has 
never been disproved. On the contrary, several studies 
have demonstrated a rise in myocardial IMP levels 
during ischaemia8 22 and especially during anoxia. 23 
Our experiments have shown that at least 60% of 
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purines released during ischaemia is derived from 
AMP-adenosine. However, part of the remaining 
40% is probably due to AMP-deaminase (EC 3 .5.4.6) 
activity in the heart. A lower energy charge (as is 
found during ischaemia) deinhibits AMP-deaminase 
activity. 24 In addition, the importance of cytosolic 
5'-nucleotidase has become apparent. It has been 
reported for this enzyme that Km values for IMP are 
lower than those for AMP (see ref25), which makes it 
possible that any IMP formed is broken down quickly 
to inosine. Another possible source of myocardial 
purine release is breakdown of GMP to guanosine, 
guanine, xanthine and uric acid. This possibility has 
not been investigated. Recently, however, we have 
studied hypoxanthine incorporation into isolated rat 
hearts after ischaemia. We demonstrated that 25% of 
hypoxanthine was built into guanine nucleotides. 15 
These results showed a relatively active guanine 
nucleotide metabolism in rat heart after ischaemia. 
Still, the incorporation of hypoxanthine (via IMP) into 
AMP is very small compared with normoxic and 
ischaemic purine release. 15 Therefore it does not 
influence purine release in our experiments where 
adenosine or EHNA was infused. 
In conclusion, we have demonstrated that 
deamination is the main pathway of catabolism of 
exogenous adenosine in the isolated perfused rat heart, 
even at low (1 ,u.mol·litre~ 1 ) concentration of 
adenosine. Furthermore, AMP breakdown in 
ischaemic rat hearts proceeds for 60% via adenosine 
formation. Lastly, we suggest that a considerable part 
of purines released from the heart is derived from IMP 
or GMP breakdown. 
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Myocardial adenosine cycling rates during normoxia and under 
conditions of stimulated purine release 
Peter W. ACHTERBERG.* Rutger J. STROEVE and Jan Wiliem DEJONG 
Cardiochemical Laboratorv, Thoraxcentre. Erasmus University Rotterdam. P.O. Box 1738. 3000 DR Rotlerdam, 
The 1'\etherlands · 
Formation and rephosphorylation of adenosine (adenosine cycling) was studied in isolated rat hearts during 
normoxia and under conditions of stimulated purine formation. Hearts were infused with an inhibitor of 
adenosine kinase (5-iodotubercidin. 2 p:-.1). In addition, perfusions were carried out with or without acetate, 
which is converted into acetyl-CoA. with simultaneous breakdown of ATP to AMP and purines. We found 
a linear, concentration-dependent. increase in norm oxic purine release by acetate (5-20 mM). Differences in 
total purine release with or without iodotubercidin were taken as a measure of adenosine cycling. In normoxic 
hearts. iodotubercidin caused a minor increase in purine release (2.7 nmoljmin per g wet wt.). Acetate 
(12.5 mM) increased purine release by 4.9 nmoljmin per g, and its combination with inhibitor gave a large 
increase. by 14.2 nmoljmin per g. This indicates a strongly increased adenosine cycling rate during acetate 
infusion. However. no significant differences in purine release were observed when iodotubercidin was infused 
during hypoxia. anoxia or ischaemia. The hypothesis that adenosine cycling is near-maximal during 
normoxia was not confirmed. Increased myocardial adenosine formation appears to be regulated by the 
availability of AMP and not by inhibition of adenosine kinase. This enzyme mainly functions to salvage 
adenosine in order to prevent excessive loss of adenine nucleotides. 
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Regulation of coronary blood flow by adenosine has 
been extensively studied (for review, see Berne, 1980). 
Chronotropic and dromotropic influences of adenosine 
on the heart have also been reported (Belardineili eta!., 
1980) as well as anti-catecholaminergic effects (Schrader 
et al., 1977). Several enzymes are involved in the 
regulation of myocardial adenosine metabolism. Forma-
tion of adenosine can take place via 5' -nucleotidase 
(EC 3.1.3.5) or S-adenosylhomocysteine hydrolase 
(EC 3.3.1.1) (Schrader era!., 1981; Schiitz el a!.. 1981; 
Achterberg era!., 1985a). The latter enzyme is also known 
to bind substantial amounts of intracellular adenosine 
(Ueland & Saebo, 1979). Removal of adenosine occurs by 
adenosine deaminase (EC 3.5.4.4) or adenosine kinase 
(EC 2.7.1.20) and by release and washout. One 
hypothesis for the regulation of adenosine production 
and concentration (Arch & Newsholme, 1978a) assumes 
that a substrate cycle exists between adenosine and AMP 
(see Scheme !) at near-maximal activity of adenosine 
kinase. Kinetic studies on purified adenosine kinase from 
rat heart (DeJong. 1977; DeJong era!.. 1980; Fisher & 
Newsholme, 1984) suggest that the above-mentioned 
hypothesis is feasible. However. Newby et a/. (1983) 
infused the adenosine kinase inhibitor 5-iodotubercidin 
into isolated rat hearts and concluded from adenosine 
and inosine release that adenosine cycling in norm oxic rat 
heart is virtually absent. However, in the latter study not 
all adenosine catabolites were determined. The present 
paper reports the determination of myocardial adenosine-
cycling rates during normoxia and under conditions 
Schemel. Metabolic pathways invoh'ed in cycling and bweak-
dowta of adenosine in the heart 
* represents adenosine cycling; broken line represents 
hypoxanthine salvage. 
where release of myocardial purines was stimulated, e.g. 
10\V-flow ischaemia, hypoxia, anoxia or infusion of 
acetate during normoxia. Our data demonstrate that in 
normoxia the adenosine-cycling rate is low. but can be 
increased by acetate infusion. 
MATERIALS AND METHODS 
Chemicals 
All chemicals were analytical grade. Water (used for 
h.p.l.c. buffers and perfusion media) was purified with the 
Abbreviati<>n u.>ed: 5· fTu, 5-iod<>tubercidin i 4"arnino-5-wdo· 7 ·(;J-I)-ribofuran<>>yl)·pyrrolo[2,3-d]p}Tirnidine) 
• To whom corrcsp<>ndcnce and r~print requests should be addres>~d 
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Milli-Ro4jMilE-Q system (Millipore CD .. Bedford. \II A. 
U.S.A.). 5-Iodotubercidin (5-ITu; NSC 113939) v..-as 
obtained through the courtesy of Dr. H. B. Wood Jr. 
(National Cancer Institute. Bethesda, MD, U.S.A.). 
Perfusion of hearts 
Male Wistarrats (275-350 g), fed ad libitum, were used. 
After anaesthesia of the rats with pentobarbital 
(intraperitoneally), hearts were quickly excised and 
immediately arrested in ice-cold 0.9% NaCI or perfusion 
buffer, a modified Tyrode solution, containing 10 mM-
glucose (Harmsen et a!., 1984). The Langendorf[ 
preparation was used with 100 cmH 10perfusionpressure. 
Hearts were paced at 300 beatsjmin (4 V stimulation for 
2 ms). Perfusion temperature was kept at 37.0 ± 0.5 °C. 
The medium was not recirculated and was gassed with 
O~JC02 (19: 1). Hypoxia was induced by gassing the 
perfusion medium with Nj0 2 jCO, (13: 6: 1). and anoxia 
by gassing with N 2/CO, (19: 1). If sodium acetate 
(5-20 mM) was added to the perfusate, glucose (10 mM) 
remained present; Na+ was kept constant by decreasing 
the concentration of NaCI in the perfusion medium in 
accordance with the increase in sodium acetate. Ischaemia 
was induced by lowering perfusion pressure to 
15-20 cmH20. At the end of the perfusion hearts were 
taker. from the apparatus, blotted dry and weighed. 
Normoxic preperfusion (15 min) preceded perfusion 
with modified medium (15 min) and was again followed 
by normoxic reperfusion (15 min). 
Coronary flow 
Mean coronary flow was determined by collection of 
perfusate in a graduated cylinder over 5 min periods. [t 
was expressed as mljmin per g wet wt. The flow measured 
between 10 and 15 min preperfusion was taken as lOOj~. 
Myocardial function 
Apex displacement was used as an indicator of 
myocardial performance. It has been shown to correlate 
well with changes in myocardial pressure development 
during ischaemia, hypoxia and anoxia (Starn & DeJong, 
1977). The displacement observed 15 min after the start 
of the perfusion was taken as 100%. 
Assay of purines 
Adenosine, inosine. hypoxanthine, xanthine and u·.-ic 
acid were determined by a slightly modified version of the 
h.p.l.c. method described by Harmsen eta!. (1984). In 
brief, 200 pl of perfusate were injected on to apBondapak 
C18 column (30 em x 0.4 em; Waters Associates. Mil-
ford, MA, U.S.A.) and eluted isocratically with 
70 m:v~-KH"PO.J, pH 4.5, to which methanol was added. 
Flow rate was either 1 or 3 mljmin (100 or 30 ml of 
methanol added to I litre of buffer respectively). Peak 
heights. detected at 254 nm, were compared with those of 
standards. Perfusates were collected on ice and transferred 
to the h.p.Lc. equipment, where temperature was kept 
belov,· 5 °C. 
Statistics 
Results a~e presented as means ±s.E.M. Statistical 
significance was evaluated by using Student's r test for 
paired or unpaired observations, and P values were 
calculated. P;;: 0.05 was considered not significant 
P. W. Achterberg, R. J. Stroeve and J. W. DeJong 
RESI;LTS 
Normoxia 
Purine release from isolated normoxic rat hearts 
decreased gradually from about 5.5 nmoljmin per g after 
15 min preperfusion to 2-3 nmoljmin per gat the end of 
the 45 min perfusion period. When the adenosine kinase 
inhibitor 5-!Tu (2 fJM) was infused, the basic purine 
release was increased by 2.7 nmoljmin per g (P < 0.05). 
Acetate (5-20 mM) was infused because it can increase 
intramyocardial AMP and purine release, which 
amounted to 4.9 nmoljmin per gat 12.5 mM-acetate. The 
combination of acetate and 5-JTu, however. caused a 
very strong increase in myocardial purine release (by 
14.2 nmoljmin per g), which was significantly greater 
(P < 0.05) than the combined increases that were caused 
by acetate and 5-ITu alone. This reflects increased 
adenosine kinase activity (adenosine cycling) during 
acetate infusion. In Fig. 1 the total purine release over the 
entire perfusion period is given for control hearts and 
hearts infused with acetate, 5-!Tu. or the combination. 
The contribution of adenosine. inosine, hypoxanthine, 
xanthine and uric acid to the total release in these 
experiments is shown in Fig. 2. Uric acid plus xanthine 
contribute 60--80% to the total release and therefore also 
to observed increases in release. Acetate infusion 
(5-10 mM) gave a linear, concentration-dependent, 
increase in normoxic purine release (by 7 nmoljmin per 
gat 20 mM-acetate). All increases in purine release were 
computed for individual hearts by subtracting the average 
of pre- and post-experimental control release from the 
release during the last 5 min of experimental infusion. 
20 r~ J I 
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Fig. I. Total purine release from isolated rat hearts perfused with 
iodotuberddin, acetate or both 
Purine release (nmoljmin per g wet wt.) is the average of 
total release over 5 min periods. From 15 to 30 min. 
acetate. iodotubercidin or both were infu5ed. Q, Controls~ 
0. combined controls: V, 12_5 mM-acetate: @1, 5-!Tu 
(2 fiM): '\1. acetate plus 5-!Tu Vertical bars indicate s.~.M 
lor four to six experiments 
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Fig. 2. Composition of total purine release during perfusion with 
iodotubercidin, acetate or both 
Release of uric acid, xanthine. hypoxanthine. inosine and 
adenosine (subdivision of bars from bottom upwards) is 
given at the end of preperfusion (Cl), at the end of 
reperfusion (C2) and during the last 5 min of infusion of 
acetate (Ac), 5-ITu or the combination (E) (see also the 
legend to Fig. I and the Materials and methods section). 
Acetate caused a concentration-dependent increase in 
coronary flow, ranging from 130 to I 65% of control flow. 
Infusion of S-ITu gave a very strong vasodilation, both 
in the presence of acetate (220% of control flow; 
P < 0.05) and when given alone (240% of controls; 
P < 0.05). Apex displacement, which was used as an 
index of myocardial contractility. was not significantly 
changed by infusion of acetate with or without 5-ITu. 
H}·poxia, anoxia, ischaemia 
Perfusion of hearts with medium gassed with 
02jN~JC02 (6: 13: 1) (hypoxia) caused an increase in 
normoxic purine release (to 9 nmoljmin per g). No 
significant differences in purine release were observed 
when 5-ITu (2 pM) was present during hypoxia (Fig. 3a). 
Coronary flow increased to 130-140% of control values 
(P < 0.05) and contractility decreased to 85/~ of controls 
p < 0.05). 
When hearts were made anoxic (N~JC02 , 19: 1), a very 
strong increase in purine release was observed (to 
72 nmoljmin per g). The presence of 5-ITu gave a non-
significant decrease in purine release as compared with 
anoxia alone (to 61 nmoljmin per g) (fig. 3c). The only 
observable effect of 5-ITu on anoxic purine release is the 
fact that the relative contribution of adenosine to total 
purine release is higher (28 versus 22% of total; P < 0.05) 
when 5-ITu is infused. 
Anoxia caused a significant increase in coronary flow 
to 150% of controls (P < 0.05) and a strong decline in 
apex displacement (to 15%; P < 0.05) at the end of 
anoxia. Reoxygenation (15 min) gave a 70% return of 
contractility. No differences in flow or contractility were 
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Fig. 3. Influence of iodotubercidin on myocardial purine release 
during hypoxia (a), ischaemia (b) and anoxia (c) 
Total purine release during the last 5 min of hypoxic (30% 
O,), ischaemic or anoxic (0% 0 2) perfusion was determined 
in the presence(+) or absence(-) of 5-ITu (2pM). 
Subdivisions of bars represent (from bottom up): uric acid, 
xanthine, hypoxanthine. inosine, adenosine. Vertical bars 
bdicate S.E.M. for three to six experiments. Note the 
Cifference in scale between hypoxia and the others. 
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Fig. 4, Contribution of uric acid, inosine and adenosine to total 
purine release under various conditions 
The rele-ase of uric acid ( 8 ). inosine (A) and adenosine (0) 
is plotted as a percentage of total purine release under 
conditions of varying purine release (i.e. nonnoxia, 
hypoxia. anoxia, ischaemia). Each point is the average of 
three to six experiments 
observed in the presence of 5~ITu during anoxia or 
hypoxia. 
Decreasing the perfusion pressure to 20-25% of 
control resulted in a strongly decreased coronary flow (to 
6--8% of control) and a purine releaseof30 nmoljmin per 
g. Infusion of 5-ITu caused a non-significant increase in 
ischaemic purine release, to 35 nmoljmin per g (Fig. 3b). 
In both groups apex displacement declined to 
22.4± 13.4% of controls (P < 0.05). Apex displacement 
tended to be higher (non-significantly) when 5-ITu was 
infused during anoxia and ischaemia. 
The relative contribution of the various purines to total 
purine release changed gradually when the total purine 
16 
release was increased (Fig. 4). The contribution of uric 
acid decreased from 70% (normoxic release) to less than 
5% (anoxia) and the contribution of inosine increased 
from 10 to 50% (both P < 0.05). The relative release of 
adenosine increased gradually from less than 5 to about 
25% of total purine release (P < 0.05). 
DISCUSSION 
Newby el al. (1983) reported that isolated normoxic rat 
hearts perfused with the adenosine kinase inhibitor 5-lTu 
do not release increased amounts of adenosine and 
inosine. It was hypothesized, however (Arch & News-
holme, 1978a; Fisher & Newsholme, 1984), that basic 
adenosbe cycling takes place in the heart at near-maximal 
adenosiile kinase activity. This activity is reported to be 
in the range of 100--200 nmoljmin per g wet wt. in rat 
heart homogenates (Arch & Newsholme, 19786) and to 
be about 30-40 nmoljmin per g when adenosine is 
infused into isolated rat hearts (Aussedat el a/., 1984; 
Newby et al .. 1983). It was therefore expected that 
inhibition of adenosine kinase during normoxia should 
lead to highly increased formation and release of 
adenosine and its catabolites. However, because of very 
rapid breakdown of adenosine, a major part of purines 
that are released from adult normoxic rat hearts consists 
of uric acid and xanthine (Ronca-Testoni & Borghini, 
1982; Schoutsen et al., 1983: Achterberg et al., !985a,b). 
The reported absence of an effect of 5-ITu on release of 
adenosine and inosine might therefore be explained by 
assuming that the expected increase would be expressed 
mainly in the release of xanthine and uric acid. In our 
hands, infusion of 5-ITu (2 p;M) into normoxic rat hearts 
indeed gave a small but significant increase (2.7 nmoljmin 
per g wet wt.) in total purine release, of which 60--80% 
could be accounted for by xanthine and uric acid. The 
efficacy of 5-ITu as inhibitor of adenosine kinase in this 
experimental set-up is essentiaL It was shown (Newby 
et al.. 1983) that 5-ITu (I p:M) inhibits the incorporation 
of ['"C]adenosine (10 ,u.M) into the myocardial adenine 
nucleotide pool by more than 90% and also that 5-ITu 
accumulated intracellularly. It still remained to be 
demonstrated that 5-ITu infusion could indeed be used 
to measure adenosine cycling, for instance when cycling 
in normoxic hearts takes place at a higher rate. With this 
in mind, acetate (5~20 mM) was infused into normoxic 
hearts, and a concentration-dependent increase in purine 
release was found. Acetate is readily taken up by the heart 
(Taegtmeyer et al., 1980) and transformed into acetyl-
CoA. In the course of this reaction, AMP is formed from 
ATP. Elevation of intracellular AMP content by acetate 
has been described for isolated rat heart (Williamson, 
1965) and for dog muscle in vivo (Liang & Lowenstein. 
1978). The latter authors also report elevation of 
coronary-sinus purine release and coronary vasodilation 
during acetate infusion. The hypothesis that adenosine-
cycling rate is normally high also predicts a decrease in 
cycling rate when adenosine formation is increased. 
However, simultaneous infusion of acetate and 5-ITu 
gave a much greater increase in purine release 
(14.2 nmoljmin per g) than the sum of increases caused 
by acetate (4.9 nmoljmin per g) and 5-ITu (2.7 nmoljmin 
per g) alone. This clearly demonstrates increased 
adenosine-cycling activity in the presence of acetate. In 
addition, these results show that infusion of 5-ITu is 
useful to determine adenosine-cycling rates in isolated 
P. W. Achterberg, R. J. Stroeve and J. W. DeJong 
perfused rat hearts. No significant cycling rates could be 
detected, however, during hypoxia, anoxia or low-flow 
ischaemia. Relatively high adenosine-cycling rates 
(20 nmoljmin per g of liver) have been reported 
(Bon temps et al., 1983) in cultured rat hepatocytes during 
incubation with 5-ITu. However, these cultures continu-
ally release substantial amounts of purines. Intercellular 
adenosine exchange, which is not the same as adenosine 
cycling. can take place more easily in cell cultures than 
in the perfused heart, because in the latter system any 
adenosine formed will be more rapidly washed out. 
Newby et al. (1983) reported that incorporation of 
infused adenosine into isolated perfused rat heart 
continued at a high rate (33 nmoljmin per g) during 
severe hypoxia. This suggests that adenosine kinase is not 
inhibited and that cycling could take place, if adenosine 
is available at the site of adenosine kinase activity. These 
results and ours could be explained by assuming that 
adenosine formation takes place at a site distant from 
adenosine kinase or that a major part of purine formation 
takes place via AMP---~ IMP··~ inosine, thereby bypassing 
adenosine formation (Achterberg et a!., 1985a,6). 
Evidence has been presented (Rovetto & Williams, 1983) 
that myocardial adenosine formation from AMP is a 
transmembrane process by which adenosine is fanned 
and released at an extracellular site. 
Both the maximal incorporation rates of infused 
adenosine(Namm, 1973; Reibel & Rovetto, 1979; Newby 
et al., 1983: Aussedat eta!., 1984) and the cycling rates 
that we found in this study are at least 2-fold lower than 
the maximal adenosine kinase activities that were 
reported in vitro (Arch & Newsholme, l978b; Newby 
et al.. 1983). This points either to a strong inhibition of 
intracellular adenosine kinase (but see Newby et at., 1983) 
or to a rate-limiting effect of adenosine transport in 
incorporation studies (Bowditch eta/.. 1985). 
Significant effects of adenosine on coronary flow are 
observed at less than 0.1 p:M-adenosine in the perfusion 
fluid (Schrader et al., 1977). It can be computed that an 
increase in adenosine formation of less than 2 nmoljmin 
per g wet wt. will be sufficient for significant coronary 
vasodilation. A minor shift in the adenylate kinase 
equilibrium (Newsholme & Start. 1973) can probably 
cause the increase in AMP that is needed for such a low 
adenosine production. During acetate infusion and 
hypoxia a good correlation is found between total purine 
release and coronary flow (results not shown). The fact 
that no increases in adenosine concentrations were found 
can be explained by the rapid breakdown of adenosine 
to uric acid (Achterberg et a/., 19856). 
The acetate-induced increase in purine release and 
coronary vasidilation that we observed is presumably 
adenosine-mediated and similar to the reported coronary 
vasodilation caused by fatty acids (HUlsmann, 1976). 
Acetate (20 mM) cz.used a 65% increase in coronary flow. 
but a 3-4-fold increase in purine release, which indicates 
that increased washout is not the cause of increased 
purine release. 
The relative contributions of the various purines to 
total purine release (Fig. 4) again emphasizes the 
importance of measuring all catabolites in these kinds of 
studies. 
Re-incorporation of hypoxanthine could theoretically 
cause an underestimation of total purine formation (see 
Scheme 1). However, Harmsen et al. (1984) have shown 
that the rate of hypoxanthine salvage is at least one order 
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of magnitude lower than norm oxic purine release, even 
when this salvage is stimulated by infusion of ribose or 
after ischaemia. 
It appears that the main importance of adenosine 
kinase is to salvage the myocardial adenine nucleotide 
pool (Newby, 1985). Our experiments with 5~ITu show 
that half of the amount of purines produced can be 
salvaged through adenosine kinase at low and mildly 
increased rates of purine production. This allows a 
maximal cellular signal (adenosine concentration) with a 
minimal waste of ATP. Our final conclusion is that 
adenosine production, insofar as it is relevant to coronary 
vasodilation, is regulated not by inhibition of adenosine 
kinase, but most probably by the intracellular AMP 
concentration. Adenosine kinase appears mainly to be 
involved in salvage of the myocardial ATP pool, for 
example during increased adenosine production caused 
by high rates of fatty acid activation. 
We thank Mrs. M. J. Kanter>-Stamfortypingthemanuscript. 
P.W.A. was supported by the Netherlands Foundation for 
Medical Research (FUNGOfZWO). 
REFERENCES 
Achterberg, P. W., De Tom be. P. P .. Harmsen. E. & DeJong, 
1. W. (l985a) Biochim. Biophys. Acta 840. 393-400 
Achterberg, P. W., Harmsen. E. & De Jong, J_ W. (1985b) 
Cardiovasc. Res. 19, 593-598 
Arch,J. R. S. & Newsholme.E. A- (l978a)Essays Biochem. 14. 
82-123 
Arch. J_ R. S. & Newsholme, E. A. (1978b) Biochem. J. 174. 
965-977 
Aussedat, J., Verdys. M_ & Rossi, A. (1984) Arch. Int. PhysioL 
Biochim. 92. 203-217 
Belardinelli. L, Bel!oni, F. L., Rubio, R. & Berne. R. M. (1980) 
Circ. Res. 47.684--691 
Berne. R. M. (1980) Circ. Res. 47.807-813 
Received 4 September 1985/31 October 1985: accepted 12 November 1985 
Vol. 235 
17 
Bon temps, F., Van den Berghe, G. & Hers, H.-G. (1983) Proc. 
Nat!. Acad. Sci. U.S.A. 80. 2829-2833 
Bowditch. J., Brown, A. K. & Dow, J. W. (1985) Biochim. 
Biophys. Acta 844. 119-128 
DeJong. J. W. (1977) Arch. Int. Physic!. Biochim. 85, 557-569 
DeJong, J. W., Keijzer. E., UitendaaL M.P. & Harmsen. E. 
(1980) Anal. Biochem. lOI, 407-412 
Fisher, M. N. & Newsholme. E. A. (1984) Biochem. J. 221. 
521~528 
Hannsen, E., De Tombe, P. P., DeJong, J. W. & Achterberg, 
P. W. (1984) Am. J. Physic!. 246. H37-H43 
HU!smann, W. C. (1976) Basic Res. Cardiol. il, 179-191 
Liang. C-S. & Lowenstein. J. M. (1978) J. Clin. ln'lest. 62. 
1029-1038 
Namm. D. H. (1973) Circ. Res. 23,686---695 
Newby. A. C. (1985) Biochem. J. 226,343-344 
Newby, A. C., Holmq~tist, C. A., I!lingworth, J. & Pearson, 
J.D. (1983) Biochem. J. 214, 317-323 
"'\lewsholme, E. A. & Start. C. (1973) Regulation in Metabolism, 
pp. 111-113. John Wiley and Sons, London 
ReibeL D. K. & Rovelto. M. 1. (1979) Am. J Physiol. 237, 
H247-H252 
Ronca-Testoni, S. & Borghini, F. (1982) J. Mol. Cell. Cardiol. 
14, 177-180 
Rovetto, M. J. & Williams. D. 0. (1983) in Regulatory 
Function of Adenosine (Berne, R. M .. Rail, T. W. & Rubio. 
R .. eds.), pp. 536---537, Martinus NijhoffPublishers, Boston 
Schoutsen, B .. DeJong, J. W., Harmsen, E., De Tombe. P. P. 
& Achterberg, P. W. (1983) Biochim. Biophys. Acta 762, 
519-524 
Schrader, J., Baumann. G. & Gerlach, E. (1977) PftUge::s Arch. 
372, 29-35 
Schrader. J., SchUtz. W. & Bardenheuer. H. (1981) Biochem. J. 
196.65-70 
Schiltz. W., Schrader. J_ & Gerlach, E. (1981) Am. J. Physiol. 
240, H963-H970 
Starn, H. & DeJong, J. W. (1977) J. Mol. Cell. Cardiol. 9, 
633-650 
Taegtmeyer. H., Hems. R. & Krebs, H. A. (1980) Biochem. J. 
186,701-711 
Ueland. P.M. & Saeb0, J_ (1979) Biochim. Biophys. Acta 587. 
341-352 
Williamson. J. R- (1965) J. Bioi. Chern. 240. 2308-232" 
